UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

American Society of Hematology Annual Meeting

December 7-10, 2019
Orlando, FL
UCSF Presentation Brochure





UCSF Helen Diller Family Comprehensive Cancer Center





UCSF

Alan Ashworth, PhD, FRS

President,
UCSF Helen Diller
Family Comprehensive
Cancer Center

Senior Vice President
for Cancer Services,
UCSF Health

Professor of Medicine,
Division of
Hematology/Oncology,
Department of Medicine

EXCEPTIONAL PEOPLE EXTRAORDINARY SCIENCE

For the past five years, it has been my privilege to work with UCSF's team of exceptional cancer scientists who are helping to transform cancer into a manageable disease, and hopefully one day, a curable disease. Among our many programs, UCSF faculty are driving efforts to overcome drug resistance, a key limitation of targeted therapy; developing drugs against previously undruggable proteins; and making significant advances in cryo-electron microscopy that is allowing scientists to visualize a broad spectrum of proteins at resolutions approaching crystal structure resolutions. We are leading the way on the next generation of cellular therapies, with novel approaches to addressing specificity and efficacy, while minimizing side effects. Also, we've expanded our state-of-the-art cancer imaging program to more rapidly assess disease progression and treatment response, creating time to move patients to other therapies when first-line therapies fail.

All of us are working in an exciting new era of collaboration. We recognize that bringing advancements to patients is best accomplished by working in partnership with the broader life science industry. As an NCI-designated comprehensive cancer center, UCSF is recognized for our outstanding science, extensive resources, depth and breadth of our research in basic, clinical, and population sciences, as well as cutting edge research that bridges these scientific areas. UCSF is home to many of the world's finest oncology clinicians and scientists who understand the power of partnerships. This searchable abstract book of UCSF research presented at ASH is a resource for potential partners interested in identifying world-class faculty engaged in basic science and clinical oncology research.

I invite you to learn more about our work and expertise by reaching out to our faculty during this meeting. If you have additional questions or would like assistance with your outreach, please contact the Director of Strategic Alliances for the Cancer Center: Cammie Edwards (cammie.edwards@ucsf.edu).

I wish you a very productive meeting, and we look forward to future discussions and collaborations.

Alan Ashworth, PhD, FRS

IN PURSUIT OF EXCELLENCE: RECENT AWARDS AND HONORS

(Click on link to read story)

SEPT 19, 2019

UCSF Establishes Benioff Initiative for Prostate Cancer Research with $35 Million Gift from Marc and Lynne Benioff

http://cancer.ucsf.edu/news/2019/09/19/ucsf-launches-benioff-initiative-for-prostate-cancer-research.9758

SEPT 30, 2019

Laura J. van 't Veer, PhD, to Receive 2020 Precision Medicine World Conference (PMWC) Luminary Award for Seminal Contributions to Personalized Medicine

https://www.pmwcintl.com/awards/

OCT 16, 2019

UCSF Global Cancer Program Awarded U54 Grant from National Cancer Institute to Reduce HPV-Associated Cancers in Latin America

http://cancer.ucsf.edu/news/2019/10/16/hdfccc-receives-u54-award-from-national-cancer-institute-to-reduce-hpv-associated-cancers-in-latin-america.9807

NOV 14, 2019

Davide Ruggero, PhD, Receives NCI Outstanding Investigator Award (R35) and American Cancer Society Professorship Award for Bold Work in Cancer Research

http://cancer.ucsf.edu/news/2019/11/14/acs-and-nci-honor-ruggero-for-bold-work-in-cancer-research.9900

DRIVING SCIENTIFIC INSIGHTS FORWARD: RECENT DISCOVERIES

(Click on link to read story)

FEB 11, 2019

UCSF's Novel Approach to a Therapeutic Cancer Vaccine May Provide a New Option for Patients Relapsing with AML

http://cancer.ucsf.edu/news/2019/02/11/ucsfs-novel-approach-to-a-therapeutic-cancer-vaccine-may-provide-a-new-option-for-patients-relapsing-with-aml.9380

JUN 20, 2019

UCSF Unveils Cancer Building Devoted to Precision Medicine: New Care for Adult Patients Centers on Tailoring Treatments to Individual Biology

http://cancer.ucsf.edu/news/2019/06/20/ucsf-unveils-cancer-building-devoted-to-precision-medicine.9582

SEPT 11, 2019

How a Powerful Genetic Test Matched An Infant's Cancer to a Life-Saving Therapy

http://cancer.ucsf.edu/news/2019/09/11/how-a-powerful-genetic-test-matched-an-infants-cancer-to-a-life-saving-therapy.9745

NOV 14, 2019



Researchers Halt Spread of Breast Cancer by Blocking Metastasis-Promoting Enzyme

http://cancer.ucsf.edu/news/2019/11/14/researchers-halt-spread-of-breast-cancer-by-blocking-metastasis-promoting-enzyme.9902

OUR SUCCESS IS DRIVEN BY OUR FACULTY

HDFCCC MEMBERSHIP: 465 MEMBERS & AFFILIATE MEMBERS

2 Nobel Laureates
3 Albert Lasker Award winners
8 Howard Hughes Medical Investigators
19 Members of the National Academy of Sciences
18 Members of the National Academy of Medicine
25 Fellows of the American Academy of Arts and Sciences
6 Fellows of the Royal Society

NCI
Designated Comprehensive Cancer Center

BLOOD MALIGNANCIES AND DISEASES

UCSF has over 50 scientists and clinicians working in the areas of myelodysplastic syndromes, myeloproliferative disorders, lymphomas, leukemias, myelomas, blood and marrow transplant, hemophilia, and amyloidosis. With our growing programs, combined expertise, and access to resources, UCSF faculty continue to make significant strides in understanding the biology of hematological diseases and improving patient outcomes with advanced clinical care.

WORKING TOGETHER ADVANCING THE UNDERSTANDING AND TREATMENT OF CANCER

NCI - Supported Research Programs (click on link to get more information)

- Breast Oncology
- Cancer Control
- Cancer Genetics
- Cancer Immunology
- Experimental Therapeutics
- Hematopoietic Malignancies
- Neurologic Oncology
- Pediatric Malignancies
- Prostate Cancer
- Tobacco Control

Additional Cancer Research (click on link to get more information)

- Cancer Genetics and Prevention Program
- Gastrointestinal Oncology
- Gynecologic Oncology
- Melanoma
- Multiple Myeloma
- Pancreas Cancer
- Pediatric Brain Tumor Research
- Precision Imaging of Cancer and Therapy
- Thoracic Oncology

Key Initiatives (click on link to get more information)

- Cancer Immunotherapy
- Center for BRCA Research
- Global Cancer
- Molecular Oncology
- Precision Cancer Medicine Building
- The San Francisco Cancer Initiative (SF CAN)
- University of California Cancer Consortium

CORE CAPABILITIES SUPPORTING OUR PROGRAMS

(Click on link to learn more)



Biorepository and Tissue Biomarker Technology

Provides optimal acquisition, processing, and storage of human tissue biospecimens, as well as state-of-the-art biomarker histologic detection and/or image analyses for both human and mouse tissue biospecimens.

Biostatistics

Provides statistical expertise and collaboration to the UCSF cancer research community on all phases of basic science, translational, clinical, epidemiological, and prevention research.

Cancer Imaging Research

Provides technical capabilities and scientific expertise for integrating cutting-edge, multi-modality imaging into basic, translational, and clinical research.



Computational Biology and Informatics

Provides computational biology and computational infrastructure support to the UCSF cancer research community.

CORE CAPABILITIES SUPPORTING OUR PROGRAMS

(Click on link to learn more)

Laboratory for Cell Analysis

Provides cytometric, microscopic, and genomic support and services for the UCSF cancer research community.



Preclinical Therapeutics

Offers a complete set of preclinical services and in vivo imaging devices for cancer investigators.

Small Molecule Discovery

Collaborates with academics, government labs, and pharmaceutical companies to develop unique chemical probes and drug leads that address unmet medical needs in cancer.



Tobacco Biomarkers

Serves as an analytical chemistry resource for the UCSF tobacco control and cancer research community.

PRESENTATIONS

*UCSF authors in bold

FRIDAY, DECEMBER 6, 2019

Minimal Residual Disease in Hematologic Malignancies: Testing Considerations and Challenges

Authors*: **Aaron C. Logan, MD, PhD,** Steven Coutre, MD, Prashant Kapoor, MD and Ajai Chari, MD
Abstract #:
Abstract link: https://ash.confex.com/ash/2019/webprogram/Session16442.html
Presentation Date/Time: Friday, December 6, 2019: 12:30 PM-4:30 PM
Location: Orlando Ballroom 3 (Hilton Orlando)
Presentation: Friday Satellite Symposia

Logan Research Interests: Dr. Aaron Logan is a member of the Adult Hematology and Blood and Marrow Transplantation program. His clinical research encompasses treatments for acute leukemias, myelodysplastic syndrome, post-transplant infectious complications, and graft-versus-host disease (GVHD). In addition to a clinical research program, Dr. Logan is Director of UCSF Hematologic Malignancies Tissue Bank (HMTB), which captures and archives tissue samples from blood cancer patients at UCSF upon diagnosis and during treatment. Dr. Logan has an independent research program that seeks to establish methods to quantify B and T cell reconstitution kinetics after myeloablative and reduced intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (allo-HCT) to yield insights into the effect of conditioning intensity on recovery of diversity in the adaptive immune system, and to determine whether immunologic repertoire diversity correlates with clinical outcomes, including relapse, GVHD, infections, and mixed donor chimerism.

http://cancer.ucsf.edu/people/profiles/logan_aaron.4577

Approaches To Achieve the Best Possible Outcomes in Myeloma

Authors*: S. Vincent Rajkumar, MD, Shaji K. Kumar, MD, Philippe Moreau, MD, Jesus San-Miguel, MD, PhD and **Thomas G. Martin III, MD**

Abstract #:
Abstract link: https://ash.confex.com/ash/2019/webprogram/Session16328.html
Presentation Date/Time: Friday, December 6, 2019: 12:30 PM-4:30 PM
Location: Windermere Ballroom (Hyatt Regency Orlando)
Presentation: Friday Satellite Symposia

Martin Research Interests: Dr. Thomas Martin is a leading expert in hematological malignancies and has been the principal investigator (PI) on over 25 MM clinical trials. His clinical research also includes translational studies designed to address the genetics of MM, the role of the microenvironment as well as discovery of biomarkers for patient selection and response to anti-MM therapeutics.

http://cancer.ucsf.edu/research/multiple-myeloma/mmti/mmti_team#martin

SATURDAY, DECEMBER 7, 2019

Von Willebrand Disease Minimize Menorrhagia (VWDMin) Trial

Authors*: Margaret V. Ragni, MD, MPH, Craig D. Seaman, MD, MS, Diana Gilligan, MD, Claire S. Philipp, MD, Anne T. Neff, MD, Robert F. Sidonio Jr., MD, MSc, Philip Kuriakose, MD, Tzu-Fei Wang, MD, MPH, Lynn M. Malec, MD, Rajiv K. Pruthi, MBBS, Elaine Majerus, MD, PhD, George M. Rodgers, MD, PhD, Danielle Nance, MD, Nina Hwang, MD, Barbara A. Konkle, MD, **Andrew D. Leavitt, MD,** Joseph Lasky, MD, Allison P. Wheeler, MD, Roshni Kulkarni, MD, Tammuella Singleton, MD, Dana Ivanco, Elynna Youm, Glory Koerbel, MSN, RN, Scott Rothenberger, PhD and Doris M. Rubio, PhD

Abstract #: 1130
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper124234.html
Presentation Date/Time: Saturday, December 7, 20197:30 AM-9:00 AM
Location: Hall B, Level 2
Presentation: Special-Interest Session

Leavitt Research Interests: Dr. Leavitt's research interests include bleeding disorders, hemophilia gene therapy, thrombosis, thrombosis in malignancy, iron disorders, women and bleeding disorders, hematology and OB/Gyn.

https://cancer.ucsf.edu/people/profiles/leavitt_andrew.3422

Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial

Authors*: **Catherine C. Smith, MD,** Mark J. Levis, MD, Alexander E. Perl, MD, Giovanni Martinelli, MD, Andreas Neubauer, MD, Ellin Berman, MD, Pau Montesinos, MD, PhD, Maria R. Baer, MD, Richard A. Larson, MD, Wen-Chien Chou, MD, PhD, Hisayuki Yokoyama, MD, PhD, Christian Recher, MD, PhD, Sung-Soo Yoon, MD, PhD, Jason E. Hill, Matt Rosales and Erkut Bahceci

Abstract #: 14
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper122620.html
Presentation Date/Time: Saturday, December 7, 2019: 7:45 AM
Location: W304, Level 3
Presentation: Oral

Smith Research Interests: The Smith laboratory focuses on identification of therapeutic resistance mechanisms and novel treatment strategies for acute myeloid leukemia (AML), particularly AML associated with mutations in Fms-like Tyrosine Kinase-3 (FLT3). FLT3 is the most frequently mutated gene in AML, with constitutively activating FLT3 internal tandem duplication (ITD) mutations conferring a poor prognosis. They employ a prototypical "bedside to bench and back" approach to the problem of cancer drug resistance, founded on the belief that the ultimate pathway to improved cancer therapy begins with translational studies that utilize samples from patients who have undergone therapy in real time. This strategy allows them to interrogate how tumors can evolve under the selective pressure of cancer therapy and allows them to devise ways to circumvent these evolutionary adaptations.

http://cancer.ucsf.edu/people/profiles/smith_catherine.3369

Sensing and Sensibility: Programming Smarter Chimeric Antigen Receptor T Cells

Authors*: **Wendell Lim, PhD**

Abstract #: SCI-24
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper121120.html
Presentation Date/Time: Saturday, December 7, 2019, 9:30 AM-11:00 AM
Location: Hall D, Level 2
Presentation: Scientific Program

Lim Research Interests: Living cells use genetically encoded molecular networks to monitor their environment and make sophisticated decisions. We are using synthetic biology approaches to understand how these decision-making networks function, with goal of asking how we can use this understanding to engineer new therapeutically useful cellular behaviors. We are developing a general toolkit and framework for cell engineering in order to program next generation therapeutic cells, including immune cells that can more precisely and safely sense and destroy cancer, cells that can disrupt targeted disease microenvironments, and cells that can build and regenerate tissue structures.

http://limlab.ucsf.edu/index.html

The Combination of Dexamethasone and Ruxolitinib Synergistically Attenuates Disease Manifestations in a Preclinical Model of Hemophagocytic Lymphohistiocytosis

Authors*: **Lauren K. Meyer,** Katherine Verbist, PhD, Sabrin Albeituni, PhD, Rachel Bassett, **Michelle L. Hermiston, MD,** PhD and Kim E. Nichols, MD

Abstract #: 81
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper129112.html
Presentation Date/Time: Saturday, December 7, 2019, 10:00 AM
Location: W314, Level 3
Presentation: Oral

Hermiston Research Interests: Dr. Hermiston's research interests are focused on defining the signaling networks involved in the development of lymphoid malignancies, including leukemia and lymphoma. Her team also studies how these signaling networks mediate chemotherapy resistance and how targeted therapies may restore chemosensitivity.

http://profiles.ucsf.edu/michelle.hermiston

First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial

Authors*: Luciano J. Costa, MD, PhD, **Sandy W. Wong, MD,** Arancha Bermúdez, Javier de la Rubia, María-Victoria Mateos, Enrique M. Ocio, Paula Rodríguez-Otero, MD, Jesus San-Miguel, MD, PhD, Shaoyi Li, Rafael Sarmiento, Pilar Lardelli, Allison Gaudy, Isaac Boss, Lisa M. Kelly, Michael R. Burgess, Kristen Hege and William I. Bensinger

Abstract #: 143
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper122895.html
Presentation Date/Time: Saturday, December 7, 2019, 10:30 AM
Location: Hall E1, Level 2
Presentation: Oral

Wong Research Interests: Dr. Sandy Wong graduated from Brown University with a degree in Human Biology and she earned her medical degree at the University of Massachusetts. Dr. Wong then completed her Internal Medicine residency followed by a Hematology/Oncology fellowship both at Tufts Medical Center in Boston. She joined the UCSF faculty in 2016, with a focus on multiple myeloma, light-chain amyloidosis and immunotherapy.

https://cancer.ucsf.edu/research/multiple-myeloma/mmti/mmti_team#wong

---

Precision Medicine Treatment in Older AML: Results of Beat AML Master Trial

Authors*: Amy Burd, PhD, Ross L. Levine, MD, Amy S. Ruppert, MAS, PhD, Alice S. Mims, MD, Uma Borate, MD, Eytan M. Stein, MD, Prapti A. Patel, MD, Maria R. Baer, MD, Wendy Stock, MD, Michael W. Deininger, William Blum, MD, Gary J. Schiller, MD, **Rebecca L. Olin, MD MSCE,** Mark Litzow, MD, James M. Foran, MD, Tara L. Lin, MD, Brian J. Ball, Michael Boyiadzis, MD, Elie Traer, Olatoyosi Odenike, MD, Martha L. Arellano, MD, Alison R. Walker, MD, Vu H. Duong, MD, Robert H. Collins, MD, Nyla A. Heerema, PhD, Jo-Anne Vergilio, MD, TIm Brennan, PHD, Christine Vietz, Molly Vittorio, Leonard Rosenberg, Sonja Marcus, MPH, Ashley Owen Yocum, PhD, Mona Stefanos, MBChB, Brian J. Druker and John C. Byrd, MD

Abstract #: 175
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper130201.html
Presentation Date/Time: Saturday, December 7, 2019, 12:00 PM
Location: Chapin Theater (W320), Level 3
Presentation: Oral

Olin Research Interests: Dr. Rebecca Olin specializes in treating acute leukemias, myelodysplastic and myeloproliferative disorders, and aplastic anemia, as well as patients who may require bone marrow transplantation. In her research, Dr. Olin has particular interests in the treatment of older adults with blood cancers, including those undergoing bone marrow transplant. Her work focuses on the impact of patient-reported functional status on post-transplant outcomes.

http://cancer.ucsf.edu/people/profiles/olin_rebecca.3372

The Dendritic Cell HLA-Class-II/Therapeutic Factor VIII (FVIII) Peptidome Is Influenced in Unanticipated Ways By the B-Domain of FVIII and the FVIII Chaperon Protein, Von Willebrand Factor: The Outrigger and Glycosylation-Umbrella (GUMB) Hypotheses

Authors*: Tom E. Howard, M.D., PhD, Bernadette W. Luu, MT (CLS), Marco Hofmann, MS, Marcio A. Almeida, PhD, Satish Kumar, PhD, Long V. Dinh, PhD, Henry Mead, MBA, MPH, Jerry S. Powell, MD, Miguel A. Escobar, MD, **Raja Rajalingam, PhD,** Sarah Williams-Blangero, PhD, John Blangero, PhD, Maraskovsky Eugene, PhD and Vincent P. Diego, PhD

Abstract #: 161
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper131727.html
Presentation Date/Time: Saturday, December 7, 2019, 1:00 PM
Location: W311, Level 3
Presentation: Oral

Raja Research Interests: Natural killer (NK) have been implicated in control and clearance of malignant and virally infected cells, regulation of adaptive immune responses, rejection of bone marrow transplants and autoimmunity. Human NK cells largely use a family of Human Leukocyte Antigen (HLA)-specific Killer cell Immunoglobulin-like Receptors (KIR) to recognize and respond to unhealthy target cells. KIR and HLA loci are both polygenic and substantially polymorphic, and map to distinct human chromosomes. KIR and HLA gene families segregate independently, yielding many individuals who express KIR receptors for which they lack HLA class I ligands, and vice versa, thus creating human diversity in the number and type of KIR-HLA inherited gene pairs, which potentially influences the health and disease status of a given individual. The goal of our research is to understand the diversity of KIR receptors, HLA ligands, and KIR-HLA gene combinations in populations and their relevance in human health and disease.

https://transplantsurgery.ucsf.edu/meet-the-team/basic-scientists/rajalingam-raja,-phd,-d(abhi)

Regulation of eIF4E Guides a Unique Translational Program to Steer Erythroid Maturation

Authors*: **Craig M. Forester, MD, PhD,** Gun Woo-Byeon, **Juan Oses-Prieto, PhD, Al Burlingame, PhD,** Maria Barna, PhD and **Davide M. Ruggero, PhD**

Abstract #: 156
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper129608.html
Presentation Date/Time: Saturday, December 7, 2019, 1:15 PM
Location: W331, Level 3
Presentation: Oral

CAR-T Therapy - Is it Prime-Time in Myeloma?

Authors*: **Nina D. Shah, MD**

Abstract #:
Abstract link: https://ash.confex.com/ash/2019/webprogram/Session16162.html
Presentation Date/Time: Saturday, December 7, 2019, 2:00 PM-3:30 PM
Location: Hall D, Level 2
Presentation: Education Program

Shah Research Interests: Dr. Nina Shah is an expert in cellular therapy for multiple myeloma. Her research focuses on multiple myeloma clinical trials, specifically immunotherapy and cellular therapy. She performed the first-in-human clinical trial of umbilical cord blood-derived natural killer cell therapy for myeloma and is currently one of the three lead principal investigators for the multi-center BMT CTN 1401 dendritic cell vaccine trial for myeloma patients. Additionally, she is the institutional PI for numerous cellular therapy (CAR-T) and novel immunotherapy protocols at UCSF. Dr. Shah is also interested in outcomes research for myeloma patients undergoing autologous transplantation and has led a randomized trial to determine the impact of stem cell dose on symptoms in this patient population. She is currently developing a study to investigate digital life coaching during transplant recovery.

http://cancer.ucsf.edu/people/profiles/shah_nina.8258

Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy

Authors*: Naval G. Daver, MD, Jacqueline S. Garcia, MD, Brian A. Jonas, MD, PhD, Kevin R. Kelly, MD, PhD, Sarit Assouline, MD, Joseph M. Brandwein, MD, Pierre Fenaux, MD, PhD, **Rebecca L. Olin, MD, MSCE,** Giovanni Martinelli, MD, Stefania Paolini, MD, PhD, Arnaud Pigneux, Daniel A. Pollyea, MD, Bayard L .Powell, MD, Gail J. Roboz, MD, Agostino Tafuri, MD, Norbert Vey, MD, PhD, Giuseppe Visani, MD, Karen W.L. Yee, MD, Monique Dail, PhD, Cherie Green, Whitney P. Kirschbrown, PharmD, PhD, Wan-Jen Hong, MD, Marion G. Ott, MD, PhD, Maika Onishi, MD, Jue Wang, PhD, Marina Y. Konopleva, MD, PhD and Michael Andreeff, MD, PhD

Abstract #: 229
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper123711.html
Presentation Date/Time: Saturday, December 7, 2019,m2:00 PM
Location: Chapin Theater (W320), Level 3
Presentation: Oral

Olin Research Interests: Dr. Rebecca Olin specializes in treating acute leukemias, myelodysplastic and myeloproliferative disorders, and aplastic anemia, as well as patients who may require bone marrow transplantation. In her research, Dr. Olin has particular interests in the treatment of older adults with blood cancers, including those undergoing bone marrow transplant. Her work focuses on the impact of patient-reported functional status on post-transplant outcomes.

http://cancer.ucsf.edu/people/profiles/olin_rebecca.3372

Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas

Authors*: Jeremy S. Abramson, MD, MMSc, Maria Lia Palomba, MD, Leo I. Gordon, MD, Matthew A. Lunning, DO, FACP, Michael L. Wang, MD, Jon E. Arnason, MD, Amitkumar Mehta, MD, Enkhtsetseg Purev, MD, PhD, David G. Maloney, MD PhD, **Charalambos Andreadis, MD, MSCE,** Alison R. Sehgal, MD, Scott R. Solomon, MD, Nilanjan Ghosh, MD, PhD, Tina Albertson, MD, Jacob Garcia, MD, Ana Kostic, Daniel Li, PhD, Yeonhee Kim and Tanya Siddiqi, MD

Abstract #: 241
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper127508.html
Presentation Date/Time: Saturday, December 7, 2019, 2:00 PM
Location: Hall E2, Level 2
Presentation: Oral

Andreadis Research Interests: Dr. Andreadis studies targeted therapeutics and cellular immunotherapy approaches to patients with hematologic malignancies. He is interested in the interplay of cancer genetics and pharmacogenetics as it pertains to prognosis and treatment response in patients with cancer, and especially hematologic malignancies.

http://cancer.ucsf.edu/people/profiles/andreadis_babis.3784

Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL)

Authors*: Veronika Bachanova, MD, PhD, Constantine S. Tam, MBBS, MD, Peter Borchmann, Ulrich Jaeger, MD, Joseph P. McGuirk, DO, Harald Holte, MD, PhD, Edmund K. Waller, PhD, MD, Samantha Jaglowski, MD, MPH, Michael R. Bishop, MD, **Charalambos Andreadis, MD, MSCE,** Stephen Ronan Foley, MD, FRCPC, Jason R. Westin, MD, Isabelle Fleury, MD, P Joy Ho, MBBS(Syd) DPhil(Oxon) FRACP FRCPA FFSc(RCPA), Stephan Mielke, MD, Takanori Teshima, MD, Gilles A. Salles, MD, PhD, Stephen J Schuster, MD, Richard T. Maziarz, MD, Koen Van Besien, MD, PhD, Koji Izutsu, MD, PhD, Marie Jose Kersten, MD, PhD, John M. Magenau, MD, Nina D. Wagner-Johnston, MD, Koji Kato, MD, PhD, Paolo Corradini, Jufen Chu, PhD, Irina Gershgorin, PhD, Therese Choquette, PhD, Lida Bubuteishvili Pacaud, MD and Margit Jeschke, PhD

Abstract #: 242
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper128302.html
Presentation Date/Time: Saturday, December 7, 2019, 2:15 PM
Location: Hall E2, Level 2
Presentation: Oral

Andreadis Research Interests: Dr. Andreadis studies targeted therapeutics and cellular immunotherapy approaches to patients with hematologic malignancies. He is interested in the interplay of cancer genetics and pharmacogenetics as it pertains to prognosis and treatment response in patients with cancer, and especially hematologic malignancies.

http://cancer.ucsf.edu/people/profiles/andreadis_babis.3784

Primary Plasma Cell Leukemia Outcomes Remain Dismal Despite Novel Agents and Hematopoietic Cell Transplantation

Authors*: Sagar Patel, MD, Saulius K. Girnius, MD, Binod Dhakal, MBBS, Lohith Gowda, MD, Raphael Fraser, PhD, Omar Davila, **Nina D. Shah, MD,** Muzaffar H. Qazilbash, MD, Shaji K. Kumar, MD, Anita D'Souza, MD, MS and Parameswaran Hari, MD

Abstract #: 266
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper127049.html
Presentation Date/Time: Saturday, December 7, 2019, 2:15 PM
Location: W308, Level 3
Presentation: Oral

Shah Research Interests: Dr. Nina Shah is an expert in cellular therapy for multiple myeloma. Her research focuses on multiple myeloma clinical trials, specifically immunotherapy and cellular therapy. She performed the first-in-human clinical trial of umbilical cord blood-derived natural killer cell therapy for myeloma and is currently one of the three lead principal investigators for the multi-center BMT CTN 1401 dendritic cell vaccine trial for myeloma patients. Additionally, she is the institutional PI for numerous cellular therapy (CAR-T) and novel immunotherapy protocols at UCSF. Dr. Shah is also interested in outcomes research for myeloma patients undergoing autologous transplantation and has led a randomized trial to determine the impact of stem cell dose on symptoms in this patient population. She is currently developing a study to investigate digital life coaching during transplant recovery.

http://cancer.ucsf.edu/people/profiles/shah_nina.8258

Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium

Authors*: Michael D. Jain, MD, PhD, Miriam T. Jacobs, MD, Loretta J. Nastoupil, MD, MSc, Jay Y. Spiegel, MD, FRCPC, Gao Feng, Yi Lin, MD, PhD, Matthew A. Lunning, DO, FACP, Saurabh Dahiya, MD, Lazaros J. Lekakis, MD, Patrick M. Reagan, MD, Olalekan O. Oluwole, MBBS, MPH, Joseph P. McGuirk, DO, Abhinav Deol, MD, Andre Goy, MD, Brian T. Hill, MD, Javier Munoz, MD, Julio Chavez, Aaron P. Rapoport, Julie M. Vose, MD MBA, David B. Miklos, MD, PhD, Sattva S Neelapu, MD, N. Nora Bennani, MD, **Charalambos Andreadis, MD, MSCE,** Alison R. Sehgal, MD, Armin Ghobadi, MD and Frederick L. Locke, MD

Abstract #: 245
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper129624.html
Presentation Date/Time: Saturday, December 7, 2019, 3:00 PM
Location: Hall E2, Level 2
Presentation: Oral

Andreadis Research Interests: Dr. Andreadis studies targeted therapeutics and cellular immunotherapy approaches to patients with hematologic malignancies. He is interested in the interplay of cancer genetics and pharmacogenetics as it pertains to prognosis and treatment response in patients with cancer, and especially hematologic malignancies.

http://cancer.ucsf.edu/people/profiles/andreadis_babis.3784

Rates of Laboratory Adverse Events By Chemotherapy Course for Pediatric Acute Leukemia Patients within the Leukemia Electronic Abstraction of Records Network (LEARN)

Authors*: Tamara P. Miller, MD, MSc, Kelly D Getz, Biniyam Demissei, MD, PhD, Karen R. Rabin, MD, PhD, Marla Daves, MD, Philip J. Lupo, PhD, MPH, Michael E. Scheurer, PhD, MPH, Evanette Burrows, MPH, Brian T. Fisher, DO, MSCE, Robert W. Grundmeier, MD, Judy Lee, Jennifer J. Wilkes, MD MSCE, **Lena E. Winestone, MD, MSHP,** Maria Monica J. Gramatges, MD, PhD and Richard Aplenc, MD, PhD

Abstract #: 333
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper130656.html
Presentation Date/Time: Saturday, December 7, 2019, 4:30 PM
Location: W308, Level 3
Presentation: Oral

Winestone Research Interests: Dr. Lena Winestone is clinically focused on pediatric blood and marrow transplant. Dr. Winestone's research explores racial, ethnic, and socioeconomic disparities in access to care and outcome of leukemia and lymphoma treatment. She has studied access to care across the continuum of cancer from diagnosis and clinical trial enrollment through treatment and relapse to salvage therapies. Her research has shown that patients from impoverished neighborhoods have inferior survival compared to those from high income neighborhoods in acute myeloid leukemia, acute lymphoid leukemia, and neuroblastoma. Her ongoing work investigates access to highly specialized and complex therapies such as stem cell transplant, chimeric antigen receptor T cells, and MIBG therapy.

http://cancer.ucsf.edu/people/profiles/winestone_lena.9218

Outcome in Adolescent and Young Adult (AYA) Patients Compared to Younger Patients Treated for High-Risk B-Lymphoblastic Leukemia (HR B-ALL): Report from the Children's Oncology Group Study AALL0232

Authors*: Michael J. Burke, MD, Meenakshi Devidas, PhD, Zhiguo Chen, MS, Wanda Salzer, MD, Elizabeth A. Raetz, MD, Karen R. Rabin, MD, PhD, Nyla A. Heerema, PhD, Andrew J. Carroll, PhD, Julie M. Gastier Foster, Michael J. Borowitz, MD, PhD, Brent L Wood, MD, PhD, Naomi Winick, MD, William Carroll, MD, Stephen P. Hunger, MD, **Mignon L. Loh, MD** and Eric Larsen, MD

Abstract #: 286
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper127052.html
Presentation Date/Time: Saturday, December 7, 2019, 4:45 PM
Location: W224, Level 2
Presentation: Oral

Loh Research Interests: The Loh lab has focused on translating genomic and biochemical discoveries in juvenile myelomonocytic (JMML) and acute lymphoblastic leukemia (ALL) into assays and therapies that can be incorporated into clinical trials. Their work in JMML has largely focused on dissecting the genomic landscape of JMML, including descriptions of PTPN11 and CBL mutations and the discovery of CBL as a new familial tumor suppressor gene. From these discoveries, Dr. Loh established JMML CLIA molecular diagnostic testing, which is now utilized as standard testing for patients suspected of having JMML. Dr. Loh is currently Chair of the Children's Oncology Group (COG) ALL committee starting in April 2015 and responsible for supervising and implementing the next generation of national ALL trials for children, adolescents, and young adults.

http://cancer.ucsf.edu/people/profiles/loh_mignon.3407

Changes in Intensive Care Unit Admission Rates, Organ Support, and Mortality in Patients with Acute Myeloid Leukemia: A Danish Nationwide Cohort Study

Authors*: Cecilie Velsoe Maeng, Lene Sofie Granfeldt Oestgaard, MD, PhD, Christian Fynbo Christiansen, MD, PhD and **Kathleen Dori Liu, MD, PhD**

Abstract #: 334
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper124347.html
Presentation Date/Time: Saturday, December 7, 2019, 4:45 PM
Location: W308, Level 3
Presentation: Oral

Liu Research Interests: My current research areas of interest focus on the predictive and pathogenetic role of biomarkers for both acute and chronic disease states. My long term goal is to identify and validate novel biomarkers of organ injury (specifically, the kidney and lung) that may have predictive value for disease outcomes as well as shed important insight into disease pathogenesis. In addition, I have a major interest in clinical trials in the Intensive Care Unit, with a particular focus on acute lung injury and acute kidney injury.

https://profiles.ucsf.edu/kathleen.liu

Direct Oral Anticoagulant Use and Outcomes in Patients with High and Intermediate Risk BCR-ABL-Negative Myeloproliferative Neoplasms

Authors*: **Kelly L. Schoenbeck, MD, Giselle Salmasi, MD, Miguel Carlos Cerejo, DO, Patricia A. Cornett, MD, Lloyd E. Damon, MD, Aaron C. Logan, MD, PhD, Rebecca L. Olin, MD MSCE, Andrew D. Leavitt, MD and Catherine C. Smith, MD**

Abstract #: 1165
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper129705.html
Presentation Date/Time: Saturday, December 7, 2019, 5:30 PM-7:30 PM
Location: Hall B, Level 2
Presentation: Poster

Smith Research Interests: The Smith laboratory focuses on identification of therapeutic resistance mechanisms and novel treatment strategies for acute myeloid leukemia (AML), particularly AML associated with mutations in Fms-like Tyrosine Kinase-3 (FLT3). FLT3 is the most frequently mutated gene in AML, with constitutively activating FLT3 internal tandem duplication (ITD) mutations conferring a poor prognosis. They employ a prototypical “bedside to bench and back” approach to the problem of cancer drug resistance, founded on the belief that the ultimate pathway to improved cancer therapy begins with translational studies that utilize samples from patients who have undergone therapy in real time. This strategy allows them to interrogate how tumors can evolve under the selective pressure of cancer therapy and allows them to devise ways to circumvent these evolutionary adaptations.

http://cancer.ucsf.edu/people/profiles/smith_catherine.3369

Rationale for Targeting BCL6 in MLL-Rearranged B-ALL

Authors*: Lai N. Chan, Christian Hurtz, PhD, **Huimin Geng, PhD,** Erica Ballabio, Gang Xiao, PhD, Gauri Deb, MS, PhD, Haytham Khoury, MD, PhD, Scott A. Armstrong, MD, PhD, Patricia Ernst, PhD, Ari Melnick, MD, Tom Arthur Milne, PhD and Markus Müschen, MD, PhD

Abstract #: 1239
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper131565.html
Presentation Date/Time: Saturday, December 7, 2019, 5:30 PM-7:30 PM
Location: Hall B, Level 2
Presentation: Poster

Geng Research Interests: Dr. Geng's research is focused on functional genomics and epigenomics of lymphoma and leukemia using computational approaches on genome-wide array and deep sequencing data, including RNA-seq, Whole Exome-Seq, ChIP-seq, miRNA-seq and DNA methylation eRRBS-seq. Applying bioinformatic methods coupled with in vitro and in vivo experiments, they are interested in identifying and evaluating new prognostic and disease-classification biomarkers and novel therapeutic targets for different forms of lymphoma and leukemia.

http://profiles.ucsf.edu/huimin.geng

Cage Transcriptome Analysis Reveals BCL2A1 Upregulation in FLT3-ITD/D835 Dual Mutated AML Cells Harboring Complex Co-Mutations

Authors*: Kotoko Yamatani, MD, Tomohiko Ai, MD, PhD, Kaori Saito, Haeun Yang, Koya Suzuki, PhD, Atsushi Hori, PhD, Yuko Murakami-Tonami, MD, PhD, Weiguo Zhang, MD, PhD, Bing Z Carter, PhD, Sonoko Kinjo, PhD, Kazuho Ikeo, PhD, Katayama Kazuhiro, Hironori Harada, MD, PhD, Takashi Miida, MD, PhD, **Neil P. Shah, MD, PhD,** Marina Y. Konopleva, MD, PhD, Yoshihide Hayashizaki, MD, PhD, Michael Andreeff, MD, PhD and Yoko Tabe, MD, PhD

Abstract #: 1264
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper124685.html
Presentation Date/Time: Saturday, December 7, 2019, 5:30 PM-7:30 PM
Location: Hall B, Level 2
Presentation: Poster

Shah Research Interests: The Shah lab is interested in advancing targeted therapeutics for hematologic malignancies through basic studies of in vitro and in vivo model systems to gain a better understanding of the critical vulnerabilities of malignant cells, and through translational/clinical studies of samples obtained from patients participating in early phase monotherapy clinical studies to identify, validate and override mechanisms of resistance to these agents.

http://cancer.ucsf.edu/people/profiles/shah_neil.3658

FLT3 Inhibitor Correlative Laboratory Assays Impact Outcomes in KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia (ALL) Patients Treated with Lestaurtinib: AALL0631, a Children's Oncology Group Study

Authors*: Patrick A. Brown, MD, John Kairalla, Joanne M. Hilden, MD, Zoann Eckert Dreyer, MD, Andrew J. Carroll, PhD, Nyla A. Heerema, PhD, Cindy Wang, MS, Meenakshi Devidas, PhD, William L. Carroll, MD, Elizabeth A. Raetz, MD, **Mignon L. Loh, MD,** Stephen P. Hunger, MD, Michael J. Borowitz, MD, PhD and Donald Small, MD, PhD

Abstract #: 1293
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper130564.html
Presentation Date/Time: Saturday, December 7, 2019, 5:30 PM-7:30 PM
Location: Hall B, Level 2
Presentation: Poster

Loh Research Interests: The Loh lab has focused on translating genomic and biochemical discoveries in juvenile myelomonocytic (JMML) and acute lymphoblastic leukemia (ALL) into assays and therapies that can be incorporated into clinical trials. Their work in JMML has largely focused on dissecting the genomic landscape of JMML, including descriptions of PTPN11 and CBL mutations and the discovery of CBL as a new familial tumor suppressor gene. From these discoveries, Dr. Loh established JMML CLIA molecular diagnostic testing, which is now utilized as standard testing for patients suspected of having JMML. Dr. Loh is currently Chair of the Children's Oncology Group (COG) ALL committee starting in April 2015 and responsible for supervising and implementing the next generation of national ALL trials forchildren, adolescents, and young adults.

http://cancer.ucsf.edu/people/profiles/loh_mignon.3407

In Vitro-Selected Nanobody-Based Cellular Therapy Targeting CD72 for Treatment of Refractory B-Cell Malignancies

Authors*: **Matthew Nix, PhD, Yu-Hsiu T. Lin, Huimin Geng, PhD, Makeba Marcoulis, Paul Phojanakong, Donghui Wang, Veronica Steri, PhD, Jeffrey Whitman, MD, Sagar Bapat, MD, PhD, Elliot Stieglitz, MD, Anne Deucher, MD, PhD, Kristie L White, MD, MEd, Byron C. Hann, MD, PhD and Arun P. Wiita, MD, PhD**

Abstract #: 1337
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper130938.html
Presentation Date/Time: Saturday, December 7, 2019, 5:30 PM-7:30 PM
Location: Hall B, Level 2
Presentation: Poster

Wiita Research Interests: The Wiita Lab uses a combination of genome engineering, chemical biology, bioinformatics, and quantitative mass spectrometry-based proteomics to discover basic biology and new therapeutic targets in hematologic malignancies. Particular interests include mechanisms of resistance to small molecule and immunotherapy agents, and new strategies to overcome resistance. Significant effort is being devoted to using cell surface proteomics to identify alterations in cell-surface antigens enriched in poor-prognosis settings, combined with nanobody engineering to develop novel cellular therapies to target these disease states. In addition, the Wiita Lab also includes the Stephen and Nancy Grand Multiple Myeloma Translational Initiative (MMTI) laboratory. The MMTI Lab works with academic and industry partners to perform preclinical evaluation of new small molecules and immunotherapies across a suite of in vitro, in vivo, and patient ex vivo models, with the goal of moving compounds into the clinic.

https://wiitalab.ucsf.edu

Single Cell Sequencing Reveals Evolution of Tumor Heterogeneity of Acute Myeloid Leukemia on Quizartinib

Authors*: **Cheryl A Cohler Peretz, MD, Lisa H F McGary, Tanya F Kumar,** J Hunter Jackson, Jose Jacob, Robert Durruthy-Durruthy, PhD, Chunxiao Zhang, Mark J. Levis, MD, Alexander E. Perl, MD, Anskar Yu Hung Leung, MD, PhD and **Catherine C. Smith, MD**

Abstract #: 1440
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper132105.html
Presentation Date/Time: Saturday, December 7, 2019, 5:30 PM-7:30 PM
Location: Hall B, Level 2
Presentation: Poster

Smith Research Interests: The Smith laboratory focuses on identification of therapeutic resistance mechanisms and novel treatment strategies for acute myeloid leukemia (AML), particularly AML associated with mutations in Fms-like Tyrosine Kinase-3 (FLT3). FLT3 is the most frequently mutated gene in AML, with constitutively activating FLT3 internal tandem duplication (ITD) mutations conferring a poor prognosis. They employ a prototypical “bedside to bench and back” approach to the problem of cancer drug resistance, founded on the belief that the ultimate pathway to improved cancer therapy begins with translational studies that utilize samples from patients who have undergone therapy in real time. This strategy allows them to interrogate how tumors can evolve under the selective pressure of cancer therapy and allows them to devise ways to circumvent these evolutionary adaptations.

http://cancer.ucsf.edu/people/profiles/smith_catherine.3369

Potential Genetic and Immunologic Mechanisms of Therapeutic Resistance and Disease Progression in CNS Lymphoma Elucidated Via Whole Brain Autopsy Studies

Authors*: **David A. Solomon, MD, PhD, Huimin Geng, PhD,** Raymond A. Sobel, MD, **Lakshmi Subbaraj, Mazie Tsang, MD and James L. Rubenstein, MD, PhD**

Abstract #: 1494
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper131302.html
Presentation Date/Time: Saturday, December 7, 2019, 5:30 PM-7:30 PM
Location: Hall B, Level 2
Presentation: Poster

Rubenstein Research Interests: The lab of Dr. James Rubenstein, Department of Medicine, works in the field immunotherapy and cancer. Their major interests are in the identification of genetic factors associated with relapse, in tumor cell tropism to the brain, and in defining the tumor microenvironment in order to improve the anti-tumor immune response. They are simultaneously involved in leading phase I and II trials in patients, in conducting correlative studies of the immune response in patients treated with immunotherapy, and in the development of novel preclinical models to understand disease mechanisms.

https://bms.ucsf.edu/directory/faculty/james-rubenstein-md-phd

Development of a Pathway-Directed Drug Screen Platform for Cutaneous T Cell Lymphoma Using Patient-Derived Xenograft Models

Authors*: **Chi-Heng Wu, PhD, Chen-Yen Yang, PhD, Linlin Wang, MD, PhD, Hua-Xin Gao, PhD, Rakhshandehroo Taha, Shervin Afghani, Laura Pincus, MD, Ronald Balassanian, MD, James Rubenstein, Ryan Gill, MD, PhD, Sourav Bandyopadhyay, PhD, Frank McCormick, PhD, Mark Moasser, MD and Weiyun Z. Ai, MD, PhD**

Abstract #: 1578
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper122589.html
Presentation Date/Time: Saturday, December 7, 2019, 5:30 PM-7:30 PM
Location: Hall B, Level 2
Presentation: Poster

Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium

Authors*: Miriam T. Jacobs, MD, Michael D. Jain, MD, PhD, Jay Y. Spiegel, MD, FRCPC, Loretta J. Nastoupil, MD, MSc, Yibo Li, MD, Gao Feng, Matthew A. Lunning, DO, FACP, Lazaros J Lekakis, MD, Saurabh Dahiya, MD, Patrick M Reagan, MD, Olalekan O. Oluwole, MBBS, MPH, Joseph P. McGuirk, DO, Abhinav Deol, MD, Alison R. Sehgal, MD, Andre Goy, MD, Brian T. Hill, MD, **Charalambos Andreadis, MD, MSCE,** Javier Munoz, MD, Julio Chavez, N. Nora Bennani, MD, Aaron P. Rapoport, Julie M Vose, MD MBA, David B Miklos, MD, PhD, Sattva S Neelapu, MD, Armin Ghobadi, MD and Frederick L. Locke, MD

Abstract #: 1583
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper131168.html
Presentation Date/Time: Saturday, December 7, 2019, 5:30 PM-7:30 PM
Location: Hall B, Level 2
Presentation: Poster

Andreadis Research Interests: Dr. Andreadis studies targeted therapeutics and cellular immunotherapy approaches to patients with hematologic malignancies. He is interested in the interplay of cancer genetics and pharmacogenetics as it pertains to prognosis and treatment response in patients with cancer, and especially hematologic malignancies.

http://cancer.ucsf.edu/people/profiles/andreadis_babis.3784

A Randomized Trial of EPOCH-Based Chemotherapy with Vorinostat for Highly Aggressive HIV-Associated Lymphomas: Updated Results Evaluating Impact of Diagnosis-to-Treatment Interval (DTI) and Pre-Protocol Systemic Therapy on Outcomes

Authors*: Juan Carlos Ramos, MD, Joseph Sparano, MD, Page C. Moore, PhD, Eric Siegel, Jeannette Y. Lee, PhD, Erin G. Reid, MD, MS, Richard F. Ambinder, MD, Amy Chadburn, MD, Paul G. Rubinstein, MD, Christine Durand, Ethel Cesarman, MD, PhD, Lee Ratner, MD, PhD, Robert A. Baiocchi, MD, PhD, David M. Aboulafia, MD, **Lawrence D Kaplan, MD,** Adam Capoferri, Ronald T. Mitsuyasu, MD and Ariela Noy, MD

Abstract #: 1588
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper129687.html
Presentation Date/Time: Saturday, December 7, 2019, 5:30 PM-7:30 PM
Location: Hall B, Level 2
Presentation: Poster

DNA Methylation As a Biomarker of Outcome in JMML: An International Effort Towards Clinical Implementation

Authors*: **Julia Meyer,** PhD, Maximillian Schönung, Christian Flotho, MD, PhD, **Adam B. Olshen, PhD, Mark Hartmann, PhD,** Christoph Plass, PhD, Yusuke Okuno, MD, PhD, Yoshiyuki Takahashi, MD, PhD, Norihiro Murakami, MD, PhD, Manabu Wakamatsu, MD, **Mignon L. Loh, MD,** Charlotte M. Niemeyer, MD, Hideki Muramatsu, MD, PhD, Daniel B. Lipka, MD and **Elliot Stieglitz, MD**

Abstract #: 1693
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper131279.html
Presentation Date/Time: Saturday, December 7, 2019, 5:30 PM-7:30 PM
Location: Hall B, Level 2
Presentation: Poster

Stieglitz Research Interests: Our lab focuses on juvenile myelomonocytic leukemia (JMML), a blood cancer that affects young children and is often difficult to diagnose and treat. Currently available therapies cure only half of patients, with some children experiencing an aggressive disease course while a rare group get better with very little treatment. We have now shown that presence of secondary mutations via deep sequencing or droplet digital PCR predicts a poor outcome. We have also shown that DNA methylation profiling can predict both good and poor responders at diagnosis. Lastly, we are running a clinical trial through the Children's Oncology Group for patients with relapsed and refractory JMML. This trial is testing the safety and efficacy of the oral MEK inhibitor, trametinib. This trial is based on extensive pre-clinical testing and a strong genomic rationale. This trial marks an important step towards more effectively treating patients with Ras driven leukemia using targeted agents.

https://cancer.ucsf.edu/people/profiles/stieglitz_elliot.7688

Profiling the Cell Surface Landscape of Proteasome Inhibitor-Treated and –Resistant Multiple Myeloma to Guide Immunotherapy Targeting, Diagnosis, and Biology

Authors*: **Ian Ferguson, Yu-Hsiu T. Lin, Sami Tuomivaara, PhD, Jeffrey L. Wolf, MD, Thomas G. Martin III, MD, Sandy W. Wong, MD, Nina D. Shah, MD,** Christoph Driessen, MD, Brian G. Van Ness, PhD and **Arun P. Wiita, MD, PhD**

Abstract #: 1803
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper131681.html
Presentation Date/Time: Saturday, December 7, 2019, 5:30 PM-7:30 PM
Location: Hall B, Level 2
Presentation: Poster

Wiita Research Interests: The Wiita Lab uses a combination of genome engineering, chemical biology, bioinformatics, and quantitative mass spectrometry-based proteomics to discover basic biology and new therapeutic targets in hematologic malignancies. Particular interests include mechanisms of resistance to small molecule and immunotherapy agents, and new strategies to overcome resistance. Significant effort is being devoted to using cell surface proteomics to identify alterations in cell-surface antigens enriched in poor-prognosis settings, combined with nanobody engineering to develop novel cellular therapies to target these disease states. In addition, the Wiita Lab also includes the Stephen and Nancy Grand Multiple Myeloma Translational Initiative (MMTI) laboratory. The MMTI Lab works with academic and industry partners to perform preclinical evaluation of new small molecules and immunotherapies across a suite of in vitro, in vivo, and patient ex vivo models, with the goal of moving compounds into the clinic.

https://wiitalab.ucsf.edu

Daratumumab (DARA) Plus Lenalidomide Versus Lenalidomide Alone As Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma (NDMM) after Frontline Autologous Stem Cell Transplant (ASCT): Use of Minimal Residual Disease (MRD) As a Novel Primary Endpoint in the Phase 3 Auriga Study

Authors*: **Nina D. Shah, MD,** Yana Lutska, PharmD, Huiling Pei, PhD, Ming Qi, MD, PhD, Maria Krevvata, PhD, Colleen Kane, PhD, VMD, Jon Ukropec, PhD, Thomas S. Lin, MD, PhD and Shalaka Hampras, MBBS, PhD, MPH

Abstract #: 1829
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper122471.html
Presentation Date/Time: Saturday, December 7, 2019, 5:30 PM-7:30 PM
Location: Hall B, Level 2
Presentation: Poster

Shah Research Interests: Dr. Nina Shah is an expert in cellular therapy for multiple myeloma. Her research focuses on multiple myeloma clinical trials, specifically immunotherapy and cellular therapy. She performed the first-in-human clinical trial of umbilical cord blood-derived natural killer cell therapy for myeloma and is currently one of the three lead principal investigators for the multi-center BMT CTN 1401 dendritic cell vaccine trial for myeloma patients. Additionally, she is the institutional PI for numerous cellular therapy (CAR-T) and novel immunotherapy protocols at UCSF. Dr. Shah is also interested in outcomes research for myeloma patients undergoing autologous transplantation and has led a randomized trial to determine the impact of stem cell dose on symptoms in this patient population. She is currently developing a study to investigate digital life coaching during transplant recovery.

http://cancer.ucsf.edu/people/profiles/shah_nina.8258

Dynamics of Activated CD8+ T-cells and Decreased Osteoclasts in the Tumor Microenvironment are Associated with Clinical Efficacy of Anti-PD-L1 and Anti-CD38 Combination Treatment in Relapsed or Refractory Multiple Myeloma

Authors*: Aparna Raval, PhD, Hearn Jay Cho, MD, PhD, Cherie Green, Elisabeth Wassner Fritsch, PharmD, Connie Ma, MS, Naomi Chang, MSc, Mark Yan, PhD, Mark Kockx, MD, PhD, Shine Shen, MS, Ling-Yuh Huw, PhD, Emily Balestiere, Marina Lipkind, Huang Huang, MSc, Michelle Byrtek, PhD, Dawn Colburn, PharmD, BCOP, **Sandy W. Wong, MD,** Jeffrey M. Venstrom, MD, PhD and Joanne I. Adamkewicz, PhD

Abstract #: 1907
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper123652.html
Presentation Date/Time: Saturday, December 7, 2019, 5:30 PM-7:30 PM
Location: Hall B, Level 2
Presentation: Poster

Wong Research Interests: Dr. Sandy Wong graduated from Brown University with a degree in Human Biology and she earned her medical degree at the University of Massachusetts. Dr. Wong then completed her Internal Medicine residency followed by a Hematology/Oncology fellowship both at Tufts Medical Center in Boston. She joined the UCSF faculty in 2016, with a focus on multiple myeloma, light-chain amyloidosis and immunotherapy.

https://cancer.ucsf.edu/research/multiple-myeloma/mmti/mmti_team#wong

---

Immune Reconstitution and Long-Term Outcomes Following Allo-HCT with TLI-ATG and Post-Transplant Rituximab

Authors*: V**anessa E Kennedy, MD,** Sally Arai, MD, David B Miklos, MD, PhD and Fang Wu

Abstract #: 1996
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper129804.html
Presentation Date/Time: Saturday, December 7, 2019, 5:30 PM-7:30 PM
Location: Hall B, Level 2
Presentation: Poster

Lentiviral Gene Therapy with Low Dose Busulfan for Infants with X-SCID Results in the Development of a Functional Normal Immune System: Interim Results of an Ongoing Phase I/II Clinical Study

Authors*: Ewelina Mamcarz, MD, Sheng Zhou, PhD, Timothy Lockey, PhD, Shannon Boi, PhD, Yan Koon-Kiu, PhD, Shane Cross, Pharm.D, Guolian Kang, PhD, Zhijun Ma, MD, Jose Marcos Condori, PhS, Jolanta Dowdy, MS, Jean-Yves Metais, PhD, Deanna Langfitt, PhD, Brandon Triplett, MD, Chen Li, MS, Xiwen Zhao, MSPH, Gabriela Maron, MD, Sneha Suresh, MD, Juan Carlos Aldave Becerra, MD, Joseph Church, MD, Elif Dokmeci, MD, James T Love, MD, PhD, Hedi van der Watt, MD, Ana C da Matta Ain, MD, Christa Krupski, DO, MPH, Jiyang Yu, PhD, Lance E. Palmer, PhD, William Janssen, PhD, Suk See De Ravin, MD, PhD, Mitchell J. Weiss, MD, PhD, Benjamin Youngblood, PhD, **Janel R. Long-Boyle, PharmD, PhD,** Michael M Meagher, PhD, Harry L. Malech, MD, **Jennifer Puck, MD, Morton J. Cowan, MD** and Stephen Gottschalk, MD

Abstract #: 2058
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper126746.html
Presentation Date/Time: Saturday, December 7, 2019, 5:30 PM-7:30 PM
Location: Hall B, Level 2
Presentation: Poster

Cowan Research Interests: Dr. Morton J. Cowan is chief of the Allergy, Immunology and Blood and Marrow Transplant Division at UCSF Benioff Children's Hospital San Francisco. He is recognized throughout the world for research in immunodeficiency diseases, the use of alternative donors and in utero stem cell transplantation. He performed the first bone marrow transplant at UCSF Medical Center for a child with severe combined immunodeficiency disease (SCID) in 1982, the first T-cell depleted transplant on the West Coast for a child with leukemia in 1985, and the first pure blood stem cell transplant from a parent to a child with SCID in North America. His research interests include gene therapy for SCID including X-SCID and Artemis-deficient SCID and also the use of haplocompatible transplants for children with malignant and non-malignant diseases who do not have a matched donor.

http://cancer.ucsf.edu/people/profiles/cowan_morton.3548

Updated Follow-up of the Alta Study, a Phase 1/2, Open Label, Adaptive, Dose-Ranging Study to Assess the Safety and Tolerability of SB-525 Gene Therapy in Adult Patients with Severe Hemophilia A

Authors*: Barbara A. Konkle, MD, Kimo Stine, MD, Nathan Visweshwar, MD, Thomas J. Harrington, MD, **Andrew D. Leavitt, MD,** Adam Giermasz, MD, PhD, Steven Arkin, MD, Gregory Di Russo, MD, Ashley Snyder, PharmD, MPH, Adrian Woolfson, MD, PhD and Didier Rouy, MD, PhD

Abstract #: 2060
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper122143.html
Presentation Date/Time: Saturday, December 7, 2019, 5:30 PM-7:30 PM
Location: Hall B, Level 2
Presentation: Poster

Leavitt Research Interests: Dr. Leavitt's research interests include bleeding disorders, hemophilia gene therapy, thrombosis, thrombosis in malignancy, iron disorders, women and bleeding disorders, hematology and OB/Gyn.

https://cancer.ucsf.edu/people/profiles/leavitt_andrew.3422

Combined Single-Cell DNA Genotyping and Protein Quantification (DAb-seq) in Acute Myeloid Leukemias Reveals Distinct Immunophenotypic Subsets Among Pathogenic Clones

Authors*: **Benjamin Demaree, Cyrille Delley, PhD, Cheryl Peretz, MD, Harish Vasudevan, MD, PhD,** David Ruff, Aik Ooi, PhD, **Catherine C. Smith, MD and Adam Abate, PhD**

Abstract #: 2088
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper127048.html
Presentation Date/Time: Saturday, December 7, 2019, 5:30 PM-7:30 PM
Location: Hall B, Level 2
Presentation: Poster

SUNDAY, DECEMBER 8, 2019

Sensing and Sensibility: Programming Smarter Chimeric Antigen Receptor T Cells

Authors*: **Wendell Lim, PhD**

Abstract #: SCI-24
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper121120.html
Presentation Date/Time: Sunday, December 8, 2019, 7:30 AM-9:00 AM
Location: Hall D, Level 2
Presentation: Scientific Program

Lim Research Interests: Living cells use genetically encoded molecular networks to monitor their environment and make sophisticated decisions. We are using synthetic biology approaches to understand how these decision-making networks function, with goal of asking how we can use this understanding to engineer new therapeutically useful cellular behaviors. We are developing a general toolkit and framework for cell engineering in order to program next generation therapeutic cells, including immune cells that can more precisely and safely sense and destroy cancer, cells that can disrupt targeted disease microenvironments, and cells that can build and regenerate tissue structures.

http://limlab.ucsf.edu/index.html

The Growing Landscape of FLT3 Inhibition in AML

Authors*: **Catherine C. Smith, MD**

Abstract #:
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper121021.html
Presentation Date/Time: Sunday, December 8, 2019, 7:30 AM-9:00 AM
Location: Chapin Theater (W320), Level 3
Presentation: Education Program

Smith Research Interests: The Smith laboratory focuses on identification of therapeutic resistance mechanisms and novel treatment strategies for acute myeloid leukemia (AML), particularly AML associated with mutations in Fms-like Tyrosine Kinase-3 (FLT3). FLT3 is the most frequently mutated gene in AML, with constitutively activating FLT3 internal tandem duplication (ITD) mutations conferring a poor prognosis. They employ a prototypical “bedside to bench and back” approach to the problem of cancer drug resistance, founded on the belief that the ultimate pathway to improved cancer therapy begins with translational studies that utilize samples from patients who have undergone therapy in real time. This strategy allows them to interrogate how tumors can evolve under the selective pressure of cancer therapy and allows them to devise ways to circumvent these evolutionary adaptations.

http://cancer.ucsf.edu/people/profiles/smith_catherine.3369

Using Technology in Medical Education

Authors*: **Tiffany Lucas, MD**

Abstract #:
Abstract link: https://ash.confex.com/ash/2019/webprogram/Session17201.html
Presentation Date/Time: Sunday, December 8, 2019, 8:30 AM-9:30 AM
Location: Celebration 1 (Hyatt Regency Orlando)
Presentation: Special-Interest Session

Lucas Research Interests: As a faculty member at UCSF Pediatric Hematology/Oncology, I see patients with pediatric hematologic and oncologic disorders although the majority of my time is spent in hematologic diseases such as patients with bleeding disorders, thromboses, immune cytopenias or aplastic anemia, bone marrow failure syndromes, and more. My research and academic focus is on quality improvement practices, patient safety, and medical education and I also do ongoing work in global health with the Commonwealth of the Northern Mariana Islands.

Twitter: @DrTiffanyL
https://profiles.ucsf.edu/tiffany.lin

Delivering Intensive Therapies to Older Adults with Hematologic Malignancies: Strategies to Personalize Care

Authors*: **Rebecca L. Olin, MD, MSCE**

Abstract #:
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper121168.html
Presentation Date/Time: Sunday, December 8, 2019, 9:30 AM-11:00 AM
Location: Valencia BC (W415BC), Level 4
Presentation: Education Program

Olin Research Interests: Dr. Rebecca Olin specializes in treating acute leukemias, myelodysplastic and myeloproliferative disorders, and aplastic anemia, as well as patients who may require bone marrow transplantation. In her research, Dr. Olin has particular interests in the treatment of older adults with blood cancers, including those undergoing bone marrow transplant. Her work focuses on the impact of patient-reported functional status on post-transplant outcomes.

http://cancer.ucsf.edu/people/profiles/olin_rebecca.3372

Late Effects and Subsequent Neoplasms in Survivors of Adolescent and Young Adult Acute Lymphoblastic Leukemia: A Population-Based Analysis Including Impact of Front-Line Regimen Type

Authors*: Lori S. Muffly, MD, Fran Maguire, PhD, MPH, Qian Li, MS, **Vanessa Kennedy, MD** and Theresa Keegan, PhD, MS

Abstract #: 421
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper124992.html
Presentation Date/Time: Sunday, December 8, 2019, 9:30 AM
Location: W314, Level 3
Presentation: Oral

Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling

Authors*: Jaewoong Lee, PhD, Kohei Kume, PhD, Zhengshan Chen, MD-PhD, Gang Xiao, PhD, Kadriye Nehir Nehir Cosgun, PhD, Liting Chen, PhD, Lai N. Chan, Lars Klemm, MS, Chun-Wei David Chen, PhD, Ning Ma, Ph.D, Wing C. Chan, MD, Stephen J. Forman, MD, Francesca Zammarchi, PhD, Patrick Van Berkel, PhD, Ari Melnick, MD, Vu N. Ngo, PhD, **Huimin Geng, PhD,** Selina M. Luger, MD, FRCPC, Mark Litzow, MD, **Michael T. McManus, PhD,** Nagarajan Vaidehi, PhD, Elisabeth M. Paietta, PhD, Eric Meffre, PhD, David M. Weinstock, MD and Markus Müschen, MD, PhD

Abstract #: 393
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper131270.html
Presentation Date/Time: Sunday, December 8, 2019, 10:00 AM
Location: Tangerine 2 (WF2), Level 2
Presentation: Oral

The Growing Landscape of FLT3 Inhibition in AML

Authors*: **Catherine C. Smith, MD**

Abstract #:
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper121021.html
Presentation Date/Time: Sunday, December 8, 2019, 4:30 PM-6:00 PM
Location: Chapin Theater (W320), Level 3
Presentation: Education Program

Smith Research Interests: The Smith laboratory focuses on identification of therapeutic resistance mechanisms and novel treatment strategies for acute myeloid leukemia (AML), particularly AML associated with mutations in Fms-like Tyrosine Kinase-3 (FLT3). FLT3 is the most frequently mutated gene in AML, with constitutively activating FLT3 internal tandem duplication (ITD) mutations conferring a poor prognosis. They employ a prototypical "bedside to bench and back" approach to the problem of cancer drug resistance, founded on the belief that the ultimate pathway to improved cancer therapy begins with translational studies that utilize samples from patients who have undergone therapy in real time. This strategy allows them to interrogate how tumors can evolve under the selective pressure of cancer therapy and allows them to devise ways to circumvent these evolutionary adaptations.

http://cancer.ucsf.edu/people/profiles/smith_catherine.3369

Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies

Authors*: Anthony R. Mato, MD MSCE, Lindsey E. Roeker, MD, Toby A. Eyre, MBBChir, MRCP, Ryan Jacobs, MD, Brian T. Hill, MD, Nicole Lamanna, MD, Danielle M. Brander, MD, Mazyar Shadman, MD, Chaitra Ujjani, MD, Maryam Yazdy, MD, Guilherme Fleury Perini, MD, Javier Pinilla Ibarz, MD, PhD, Jacqueline C. Barrientos, MD, Alan Skarbnik, MD, Pallawi Torka, MD, Jeffrey J. Pu, MD, PhD, John M. Pagel, MD, PhD, DSc, Satyen Gohil, MBBS, MRCP, FRCPath, **Bita Fakhri, MD, MPH,** Michael Y. Choi, MD, Catherine C. Coombs, MD, Joanna Rhodes, MD, Paul M. Barr, MD, Craig A. Portell, MD, Helen Parry, MB, ChB, MRCP, PhD, Christine Ann Garcia, MD, MPH, Kate J Whitaker, Allison M. Winter, MD, Andrea Sitlinger, MD, Sirin Khajavian, MD, Ariel F Grajales-Cruz, MD, Krista Isaac, DO, MS, Pratik Shah, Othman S. Akhtar, MD, Rachael Pocock, MD, Kentson Lam, MD, PhD, Timothy J. Voorhees, MD, Stephen J. Schuster, MD, Thomas David Rodgers, MD, Nicolas Martinez-Calle, MD, MSc, Talha Munir, MD, Erica B Bhavsar, Neil Bailey, MSc, Jason C. Lee, MD, Hanna Weissbrot, Chadi Nabhan, MD, MBA, FACP, Julie Goodfriend, Amber C. King, PharmD, BCOP, Andrew D. Zelenetz, MD, PhD, Colleen Dorsey, BSN, RN, Kayla Bigelow, Bruce D. Cheson, MD, Christopher P. Fox, MBChB(Hons), MRCP, FRCPath, PhD and John N. Allan, MD

Abstract #: 502
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper123747.html
Presentation Date/Time: Sunday, December 8, 2019, 5:15 PM
Location: Hall D, Level 2
Presentation: Oral

Fakhri Research Interests: Dr. Fakhri is a clinician-researcher with a special interest in lymphoid malignancies, clinical trials and cellular therapies. She is focused on developing trials for patients with lymphomas/CLL. She is involved in early drug development and CAR T trials for patients with CLL and lymphoid malignancies. She is also working with industry in developing projects focused on Health Economics and Outcomes Research to identify areas of unmet need for future trial development.

https://profiles.ucsf.edu/bita.fakhri

Direct Visualization of Platelet Integrins Using ANTI-Transmembrane Domain Peptides Containing a BLUE Fluorescent Amino Acid

Authors*: Karen Pei Yi Fong, PhD, Ismail A. Ahmed, PhD, **Marco Mravic, MS, Hyunil Jo, PhD, William F. DeGrado, PhD,** Feng Gai, PhD and Joel S. Bennett, MD

Abstract #: 2344
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper128363.html
Presentation Date/Time: Sunday, December 8, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children

Authors*: **Kristin A. Shimano, MD,** Rachael F. Grace, MD, Carolyn M. Bennett, MD, MSc, Robert J. Klaassen, MD, FRCPC, Cindy Neunert, MD, Ellis J. Neufeld, MD, Clement Ma, PhD, Wendy B. London, PhD and Jenny M. Despotovic, DO, MS

Abstract #: 2369
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper125487.html
Presentation Date/Time: Sunday, December 8, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

On the Role of F8 Sequence Mismatch and Class-II Human Leukocyte Antigen Binding in the Development of Neutralizing Antibodies ("Inhibitors") Directed Against Therapeutic Factor VIII Proteins (tFVIIIs): Evidence from the PATH Study

Authors*: Vincent P. Diego, PhD, Bernadette W. Luu, MT (CLS), Afshin Ameri, MD, Meera B. Chitlur, MD, Marcio A. Almeida, PhD, Karin Haack, PhD, Satish Kumar, PhD, Long V. Dinh, PhD, Henry Mead, MBA, MPH, Jerry S. Powell, MD, Miguel A. Escobar, MD, **Raja Rajalingam, PhD,** Sarah Williams-Blangero, PhD, Carol K. Kasper, MD, Laura Almasy, PhD, Shelley Cole, PhD, John Blangero, PhD and Tom E. Howard, MD, PhD

Abstract #: 2393
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper132218.html
Presentation Date/Time: Sunday, December 8, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

Raja Research Interests: Natural killer (NK) have been implicated in control and clearance of malignant and virally infected cells, regulation of adaptive immune responses, rejection of bone marrow transplants and autoimmunity. Human NK cells largely use a family of Human Leukocyte Antigen (HLA)-specific Killer cell Immunoglobulin-like Receptors (KIR) to recognize and respond to unhealthy target cells. KIR and HLA loci are both polygenic and substantially polymorphic, and map to distinct human chromosomes. KIR and HLA gene families segregate independently, yielding many individuals who express KIR receptors for which they lack HLA class I ligands, and vice versa, thus creating human diversity in the number and type of KIR-HLA inherited gene pairs, which potentially influences the health and disease status of a given individual. The goal of our research is to understand the diversity of KIR receptors, HLA ligands, and KIR-HLA gene combinations in populations and their relevance in human health and disease.

https://transplantsurgery.ucsf.edu/meet-the-team/basic-scientists/rajalingam-raja,-phd,-d(abhi)

Emicizumab-Kxwh for Previously Untreated Patients with Haemophilia: The Conversation Begins

Authors*: **Tiffany Lin Lucas, MD,** Shveta Gupta, MBBS, Joanna A. Davis, MD and Fernando F. Corrales-Medina, MD

Abstract #: 2409
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper127270.html
Presentation Date/Time: Sunday, December 8, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

Lucas Research Interests: As a faculty member at UCSF Pediatric Hematology/Oncology, I see patients with pediatric hematologic and oncologic disorders although the majority of my time is spent in hematologic diseases such as patients with bleeding disorders, thromboses, immune cytopenias or aplastic anemia, bone marrow failure syndromes, and more. My research and academic focus is on quality improvement practices, patient safety, and medical education and I also do ongoing work in global health with the Commonwealth of the Northern Mariana Islands.

Twitter: @DrTiffanyL
https://profiles.ucsf.edu/tiffany.lin

The Presence and Persistence of Pregnancy-Associated Red Blood Cell Alloantibodies in Blood Donors

Authors*: Raisa Balbuena-Merle, MD, Ronald G. Hauser, MD, Matthew Karafin, MD, Sylvia Tan, MS, Bryan R. Spencer, MPH, PhD, **Nareg Roubinian, MD,** Yanyun Wu, MD, PhD, Darrell Triulzi, MD, Steven Kleinman, MD, Jerry Gottschall, MD, Christopher A. Tormey, MD and Jeanne E. Hendrickson, MD

Abstract #: 2452
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper121388.html
Presentation Date/Time: Sunday, December 8, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

Roubinian Research Interests: Dr. Roubinian's research is focused on predictive models and trends in blood utilization as well as clinical and laboratory factors in blood donors, components, and recipients relevant to the efficacy and potential harm of blood transfusion.

http://profiles.ucsf.edu/nareg.roubinian

The Genome-Wide Impact of Trisomy 21 on DNA Methylation and Its Implications for Hematologic Malignancies

Authors*: Joseph L. Wiemels, PhD, Ivo S. Muskens Shaobo Li, Priyatama Pandey, **Ritu Roy, PhD, Helen M. Hansen,** Kimberly D. Siegmund, PhD, Beth A. Mueller, PhD, Xiaomei Ma, PhD, Catherine Metayer, MD, PhD and Adam J. de Smith, PhD

Abstract #: 2510
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper131455.html
Presentation Date/Time: Sunday, December 8, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

Open-Label, Multicenter, Phase 2/3 Study of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens (RC-P) in Patients with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to Escherichia coli–Derived Asparaginases

Authors*: Luke Maese, DO, Rachel E. Rau, MD, Elizabeth A. Raetz, MD, Tong Lin, Jin Zhu, Pil Kim, Reddy Chandula, Sherrie McClung, Julie Gray, Mi Rim Choi, MD, **Mignon L. Loh, MD** and Peter C. Adamson

Abstract #: 2586
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper123710.html
Presentation Date/Time: Sunday, December 8, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

Loh Research Interests: The Loh lab has focused on translating genomic and biochemical discoveries in juvenile myelomonocytic (JMML) and acute lymphoblastic leukemia (ALL) into assays and therapies that can be incorporated into clinical trials. Their work in JMML has largely focused on dissecting the genomic landscape of JMML, including descriptions of PTPN11 and CBL mutations and the discovery of CBL as a new familial tumor suppressor gene. From these discoveries, Dr. Loh established JMML CLIA molecular diagnostic testing, which is now utilized as standard testing for patients suspected of having JMML. Dr. Loh is currently Chair of the Children's Oncology Group (COG) ALL committee starting in April 2015 and responsible for supervising and implementing the next generation of national ALL trials forchildren, adolescents, and young adults.

http://cancer.ucsf.edu/people/profiles/loh_mignon.3407

Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/ Refractory Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Phase 1 Study

Authors*: Seth E. Karol, MD, Todd M Cooper, DO, Henrique Bittencourt, Lia Gore, MD, Maureen M. O'Brien, MD, Christopher Fraser, MD, Marion Gambart, MD, Gunnar Cario, MD, PhD, Christian Michel Zwaan, MD, PhD, Jean-Pierre Bourquin, MD, PhD, **Mignon L. Loh, MD,** Hubert Caron, MD, PhD, Betty Prine, Ahmed Hamed Salem, PhD, FCP, Kristina Unnebrink, Bo Tong, PhD, Tammy Palenski, PhD and Andrew E. Place, MD, PhD

Abstract #: 2649
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper129805.html
Presentation Date/Time: Sunday, December 8, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

Loh Research Interests: The Loh lab has focused on translating genomic and biochemical discoveries in juvenile myelomonocytic (JMML) and acute lymphoblastic leukemia (ALL) into assays and therapies that can be incorporated into clinical trials. Their work in JMML has largely focused on dissecting the genomic landscape of JMML, including descriptions of PTPN11 and CBL mutations and the discovery of CBL as a new familial tumor suppressor gene. From these discoveries, Dr. Loh established JMML CLIA molecular diagnostic testing, which is now utilized as standard testing for patients suspected of having JMML. Dr. Loh is currently Chair of the Children's Oncology Group (COG) ALL committee starting in April 2015 and responsible for supervising and implementing the next generation of national ALL trials forchildren, adolescents, and young adults.

http://cancer.ucsf.edu/people/profiles/loh_mignon.3407

Ifitm3 Is Essential for PI(3,4,5)P3-Dependent B-Cell Activation and Leukemogenesis

Authors*: Jaewoong Lee, PhD, Gang Xiao, PhD, Kadriye Nehir Nehir Cosgun, PhD, **Huimin Geng, PhD,** Ning Ma, PhD, Lai N Chan, Kohei Kume, PhD, **Matthew Nix, PhD,** Zhengshan Chen, MD-PhD, Chun-Wei David Chen, PhD, Jianjun Chen, PhD, Vishal Khairnar, PhD, **Arun P. Wiita, MD, PhD,** Andrei Thomas-Tikhonenko, PhD, Michael Farzan, MD-PhD, Michael S. Diamond, PhD, Jae U Jung, PhD, Nagarajan Vaidehi, PhD and Markus Müschen, MD, PhD

Abstract #: 2782
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper127615.html
Presentation Date/Time: Sunday, December 8, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

Geng Research Interests: Dr. Geng's research is focused on functional genomics and epigenomics of lymphoma and leukemia using computational approaches on genome-wide array and deep sequencing data, including RNA-seq, Whole Exome-Seq, ChIP-seq, miRNA-seq and DNA methylation eRRBS-seq. Applying bioinformatic methods coupled with in vitro and in vivo experiments, they are interested in identifying and evaluating new prognostic and disease-classification biomarkers and novel therapeutic targets for different forms of lymphoma and leukemia.

http://profiles.ucsf.edu/huimin.geng

A Phase I/II Trial of Intratumoral CpG, Local Low-Dose Radiation, and Oral Ibrutinib in Patients with Low-Grade B-Cell Lymphoma

Authors*: Tanaya Shree, MD, PhD, Michael S. Khodadoust, MD, PhD, Debra K. Czerwinski, Matthew J. Frank, MD, PhD, Wan X. Hong, MD, Rachel Greenstein, **Steven R. Long, MD,** Brock Martin, MD and Ronald Levy, MD

Abstract #: 2825
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper129661.html
Presentation Date/Time: Sunday, December 8, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

A Phase 1b Dose Escalation Trial of Carfilzomib in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Authors*: **Swetha Kambhampati, MD, Bita Fakhri, MD, MPH, Weiyun Ai, MD, PhD, Lawrence D. Kaplan, MD,** Joseph Tuscano, MD, Matthew J. Wieduwilt, MD, PhD Akshay Sudhindra, MD, **Jimmy Hwang, PhD,** Jesika Reiner, MPH, **Michelle Martinelli, Charlie Aoun,** Teresa Ta, Diem Le, **Michelle Padilla, Erika Crawford and Charalambos Andreadis, MD**

Abstract #: 2828
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper123279.html
Presentation Date/Time: Sunday, December 8, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

Andreadis Research Interests: Dr. Andreadis studies targeted therapeutics and cellular immunotherapy approaches to patients with hematologic malignancies. He is interested in the interplay of cancer genetics and pharmacogenetics as it pertains to prognosis and treatment response in patients with cancer, and especially hematologic malignancies.

http://cancer.ucsf.edu/people/profiles/andreadis_babis.3784

A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

Authors*: Anita Kumar, MD, Carla Casulo, MD, Ranjana Advani, MD, Lihua E. Budde, MD, PhD, Paul M. Barr, MD, Connie Lee Batlevi, MD, PhD, Philip Caron, MD, PhD, Louis S. Constine, MD, Savita Dandapani, MD, PhD, Esther Drill, PhD, Pamela Drullinsky, MD, Jonathan W. Friedberg, MD, Clare Grieve, Audrey Hamilton, MD, Paul A. Hamlin, MD, Richard T. Hoppe, MD, Steven M. Horwitz, MD, Matthew J. Matasar, MD, Susan Jennifer McCall, NP, Alison J. Moskowitz, MD, Ariela Noy, MD, Maria Lia Palomba, MD, Heiko Schoder, MD, David J. Straus, MD, Shreya Vemuri, **Joanna C. Yang, MD, MPH,** Anas Younes, MD, Andrew D. Zelenetz, MD, PhD, Joachim Yahalom, MD and Craig H. Moskowitz

Abstract #: 2834
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper123150.html
Presentation Date/Time: Sunday, December 8, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

Current Selection Patterns, Toxicities and Outcomes of Pre-Transplant Salvage Treatment Regimens in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of a Multicenter Retrospective Analysis

Authors*: Jakub Svoboda, MD, Hatcher J. Ballard, Steven M. Bair, MD, **Rahul Banerjee, MD, Charalambos Andreadis, MD,** Tatyana A. Feldman, MD, Elizabeth L. McCarthy, MSN, RN, Niloufer Khan, MD, Alison J. Moskowitz, MD, Victor M. Orellana-Noia, MD, Craig A. Portell, MD, Sarah J. Nagle, MD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Stefan K. Barta, MD, MRCP, MS, Elise A. Chong, MD and Stephen J. Schuster, MD

Abstract #: 2855
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper123741.html
Presentation Date/Time: Sunday, December 8, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

Andreadis Research Interests: Dr. Andreadis studies targeted therapeutics and cellular immunotherapy approaches to patients with hematologic malignancies. He is interested in the interplay of cancer genetics and pharmacogenetics as it pertains to prognosis and treatment response in patients with cancer, and especially hematologic malignancies.

http://cancer.ucsf.edu/people/profiles/andreadis_babis.3784

Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Ineligible Patients: Transcend NHL 001, Outreach, and PILOT

Authors*: Carlos R. Bachier, MD, Maria Lia Palomba, MD, Jeremy S. Abramson, MD, MMSc, **Charalambos Andreadis, MD, MSCE,** Alison R. Sehgal, MD, John Godwin, Gerhard C. Hildebrandt, MD, Tanya Siddiqi, MD, Don Stevens, MD, Thalia Farazi, Ana Kostic, Nikolaus S. Trede, Lei Wang, PhD, James Lymp, PhD, Tennille Thelen, Ken Ogasawara and David G. Maloney, MD PhD

Abstract #: 2868
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper127566.html
Presentation Date/Time: Sunday, December 8, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

Andreadis Research Interests: Dr. Andreadis studies targeted therapeutics and cellular immunotherapy approaches to patients with hematologic malignancies. He is interested in the interplay of cancer genetics and pharmacogenetics as it pertains to prognosis and treatment response in patients with cancer, and especially hematologic malignancies.

http://cancer.ucsf.edu/people/profiles/andreadis_babis.3784

Response-Adapted Therapy with Infusional EPOCH Chemotherapy Plus Rituximab in HIV-Associated, B-Cell Non-Hodgkin's Lymphoma

Authors*: Juan Carlos Ramos, MD, Richard F. Ambinder, MD, Joseph Sparano, MD, Jeannette Y. Lee, PhD, **Lawrence D. Kaplan, MD,** William Wachsman, MD, PhD, David M. Aboulafia, MD, Ariela Noy, MD, Lee Ratner, MD, PhD, David H. Henry, MD, Amy Chadburn, MD, Ethel Cesarman, MD, PhD and Ronald T. Mitsuyasu, MD

Abstract #: 2872
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper123558.html
Presentation Date/Time: Sunday, December 8, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel

Authors*: **Charalambos Andreadis, MD, MSCE,** Constantine S. Tam, MBBS, MD, Peter Borchmann, MD, PhD, Ulrich Jaeger, MD, Joseph P. McGuirk, DO, Harald Holte, MD, PhD, Edmund K. Waller, PhD, MD, Samantha Jaglowski, MD, MPH, Michael R. Bishop, MD, Stephen Ronan Foley, MD, FRCPC Jason R. Westin, MD, Isabelle Fleury, MD, P Joy Ho, MBBS(Syd) DPhil(Oxon) FRACP FRCPA FFSc(RCPA), Stephan Mielke, MD, Takanori Teshima, MD, Gilles A. Salles, MD, PhD, Stephen J. Schuster, MD, Veronika Bachanova, MD, PhD, Richard T. Maziarz, MD, Koen Van Besien, MD, PhD, Koji Izutsu, MD, PhD, John M. Magenau, MD, Nina D. Wagner-Johnston, MD, Koji Kato, MD, PhD, Paolo Corradini, Ranjan Tiwari, MSc, Rakesh Awasthi, PhD, Tomasz Lawniczek, MD, Lamis K. Eldjerou, MD and Marie Jose Kersten, MD, PhD

Abstract #: 2883
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper124492.html
Presentation Date/Time: Sunday, December 8, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

Andreadis Research Interests: Dr. Andreadis studies targeted therapeutics and cellular immunotherapy approaches to patients with hematologic malignancies. He is interested in the interplay of cancer genetics and pharmacogenetics as it pertains to prognosis and treatment response in patients with cancer, and especially hematologic malignancies.

http://cancer.ucsf.edu/people/profiles/andreadis_babis.3784

Cord Blood Regulatory T Cells Prevent Mutiple Myeloma Progression By Suppressing Inflammation

Authors*: Mitsutaka Nishimoto, MD, PhD, Ke Zeng, MD, PhD, Meixian Huang, Mi-Ae Lyu, PhD, **Nina D. Shah, MD,** Swaminathan P. Iyer, MD, Robert Z. Orlowski, MD, PhD and Simrit Parmar, MBBS

Abstract #: 3095
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper128418.html
Presentation Date/Time: Sunday, December 8, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

Shah Research Interests: Dr. Nina Shah is an expert in cellular therapy for multiple myeloma. Her research focuses on multiple myeloma clinical trials, specifically immunotherapy and cellular therapy. She performed the first-in-human clinical trial of umbilical cord blood-derived natural killer cell therapy for myeloma and is currently one of the three lead principal investigators for the multi-center BMT CTN 1401 dendritic cell vaccine trial for myeloma patients. Additionally, she is the institutional PI for numerous cellular therapy (CAR-T) and novel immunotherapy protocols at UCSF. Dr. Shah is also interested in outcomes research for myeloma patients undergoing autologous transplantation and has led a randomized trial to determine the impact of stem cell dose on symptoms in this patient population. She is currently developing a study to investigate digital life coaching during transplant recovery.

http://cancer.ucsf.edu/people/profiles/shah_nina.8258

Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or efractory Multiple Myeloma

Authors*: Paul G. Richardson, MD, Myo Htut, MD, Cristina Gasparetto, MD, Jeffrey A. Zonder, MD, **Thomas G. Martin III, MD,** Janice Chen, PhD, Christopher Brooks, PhD, Peter McDonald, Nicole Rupprecht, Halyna Wysowskyj, Dharminder Chauhan, PhD, Arghya Ray, PhD, Kenneth C. Anderson, MD and Claudia E. Paba-Prada, MD

Abstract #: 3145
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper130410.html
Presentation Date/Time: Sunday, December 8, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

Martin Research Interests: Dr. Thomas Martin is a leading expert in hematological malignancies and has been the principal investigator (PI) on over 25 MM clinical trials. His clinical research also includes translational studies designed to address the genetics of MM, the role of the microenvironment as well as discovery of biomarkers for patient selection and response to anti-MM therapeutics.

http://cancer.ucsf.edu/research/multiple-myeloma/mmti/mmti_team#martin

Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME)

Authors*: Caitlin L. Costello, MD, Tara K. Gregory, MD, Syed Abbas Ali, MD, Jesus G. Berdeja, MD, Krina K. Patel, MD, MSc, **Nina D. Shah, MD,** Eric Ostertag, Chris Martin, Majid Ghoddusi, PhD, DVM, Devon J Shedlock, PhD, Matthew A. Spear, MD, Robert Z. Orlowski, MD, PhD and Adam D. Cohen, MD

Abstract #: 3184
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper129562.html
Presentation Date/Time: Sunday, December 8, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

Shah Research Interests: Dr. Nina Shah is an expert in cellular therapy for multiple myeloma. Her research focuses on multiple myeloma clinical trials, specifically immunotherapy and cellular therapy. She performed the first-in-human clinical trial of umbilical cord blood-derived natural killer cell therapy for myeloma and is currently one of the three lead principal investigators for the multi-center BMT CTN 1401 dendritic cell vaccine trial for myeloma patients. Additionally, she is the institutional PI for numerous cellular therapy (CAR-T) and novel immunotherapy protocols at UCSF. Dr. Shah is also interested in outcomes research for myeloma patients undergoing autologous transplantation and has led a randomized trial to determine the impact of stem cell dose on symptoms in this patient population. She is currently developing a study to investigate digital life coaching during transplant recovery.

http://cancer.ucsf.edu/people/profiles/shah_nina.8258

Role of Disease Mechanism in Hematopoietic Cell Transplantation Outcomes for Hemophagocytic Lymphohistiocytosis

Authors*: **Aleksandra S. Dain, MD, Michelle L. Hermiston, MD, PhD, Kristin A. Shimano, MD, Sandhya Kharbanda, MD, Alexis Melton, MD, PhD, Jasmeen Dara, MD, James N. Huang, MD and Christopher C. Dvorak, MD**

Abstract #: 3343
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper127397.html
Presentation Date/Time: Sunday, December 8, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

Dvorak Research Interests: Dr. Dvorak's research interests are the supportive care aspects of pediatric hematopoietic cell transplantation (HCT), with a goal of decreasing treatment-related morbidity and mortality (especially infections), and optimizing HCT regimens for treatment of infant leukemias. Dr. Dvorak is the former Chair of the international Pediatric Blood and Marrow Transplant Consortium's (PBMTC) Supportive Care Strategy Group and Chair of the Children's Oncology Group (COG)'s Cancer Control & Supportive Care Committee. Among his clinical trials, he was the national PI of COG trial ACCL1131: An Open-Label Phase III Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections Undergoing Allogeneic HCT and the COG trial ASCT1221: A Randomized Phase II Study Comparing Two Different Conditioning Regimens Prior to Allogeneic Hematopoietic Cell Transplantation for Children with Juvenile Myelomonocytic Leukemia (JMML).

http://cancer.ucsf.edu/people/profiles/dvorak_christopher.3611

A Clinical Pathway Reduces Admissions for Vaso-Occlusive Pain in Sickle Cell Disease

Authors*: Wallace Jones, MD, Leann Myers, **Aditi Dasgupta, MD** and Jessica Debord

Abstract #: 3383
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper127097.html
Presentation Date/Time: Sunday, December 8, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

Disparities in Barriers and Facilitators of Acute Leukemia Diagnosis in Young Patients

Authors*: **Lucky Ding,** Ashley E. Martin, MPH, **Emma Canepa, MS, Erica Evans, MD,** Richard Aplenc, MD, PhD, Julia E Szymczak, Ph, **Galen Joseph, PhD and Lena E. Winestone, MD, MSHP**

Abstract #: 3415
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper124236.html
Presentation Date/Time: Sunday, December 8, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

Winestone Research Interests: Dr. Lena Winestone is clinically focused on pediatric blood and marrow transplant. Dr. Winestone's research explores racial, ethnic, and socioeconomic disparities in access to care and outcome of leukemia and lymphoma treatment. She has studied access to care across the continuum of cancer from diagnosis and clinical trial enrollment through treatment and relapse to salvage therapies. Her research has shown that patients from impoverished neighborhoods have inferior survival compared to those from high income neighborhoods in acute myeloid leukemia, acute lymphoid leukemia, and neuroblastoma. Her ongoing work investigates access to highly specialized and complex therapies such as stem cell transplant, chimeric antigen receptor T cells, and MIBG therapy.

http://cancer.ucsf.edu/people/profiles/winestone_lena.9218

MONDAY, DECEMBER 9, 2019

Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial

Authors*: Ravi Vij, MBBS, **Thomas G. Martin III, MD,** Nitya Nathwani, MD, Mark A. Fiala, Feng Gao, PhD, Abhinav Deol, MD, Francis K. Buadi, MB, CHB, Jonathan L. Kaufman, MD, Craig C Hofmeister, MD, MPH, Tara K. Gregory, MD, Jesus G. Berdeja, MD, Ajai Chari, MD and Ashley E. Rosko, MD

Abstract #: 602
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper130644.html
Presentation Date/Time: Monday, December 9, 2019, 7:15 AM
Location: Sunburst Room (W340)
Presentation: Oral

Martin Research Interests: Dr. Thomas Martin is a leading expert in hematological malignancies and has been the principal investigator (PI) on over 25 MM clinical trials. His clinical research also includes translational studies designed to address the genetics of MM, the role of the microenvironment as well as discovery of biomarkers for patient selection and response to anti-MM therapeutics.

http://cancer.ucsf.edu/research/multiple-myeloma/mmti/mmti_team#martin

---

Enhanced Transduction Lentivector Gene Therapy for Treatment of Older Patients with X-Linked Severe Combined Immunodeficiency

Authors*: Suk See De Ravin, MD, PhD, Sandra Anaya O'Brien, Nana Kwatemaa, RN, MSN, CCRP, Narda Theobald, Siyuan Liu, Janet Lee, Lela Kardava, Taylor Liu, Frederick Goldman, MD, MS, Susan Moir, Jack Bleesing, MD, PhD, Benedicte Neven, MD, PHD, **Jennifer Puck, MD, Morton J Cowan, MD,** Ewelina Mamcarz, MD, Stephen Gottschalk, MD, Michael M. Meagher, PhD, Luigi Notarangelo, MD, Elizabeth Kang, MD, Xiaolin Wu, PhD and Harry L. Malech, MD

Abstract #: 608
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper127439.html
Presentation Date/Time: Monday, December 9, 2019, 7:15 AM
Location: Valencia BC (W415BC), Level 4
Presentation: Oral

Cowan Research Interests: Dr. Morton J. Cowan is chief of the Allergy, Immunology and Blood and Marrow Transplant Division at UCSF Benioff Children's Hospital San Francisco. He is recognized throughout the world for research in immunodeficiency diseases, the use of alternative donors and in utero stem cell transplantation. He performed the first bone marrow transplant at UCSF Medical Center for a child with severe combined immunodeficiency disease (SCID) in 1982, the first T-cell depleted transplant on the West Coast for a child with leukemia in 1985, and the first pure blood stem cell transplant from a parent to a child with SCID in North America. His research interests include gene therapy for SCID including X-SCID and Artemis-deficient SCID and also the use of haplocompatible transplants for children with malignant and non-malignant diseases who do not have a matched donor.

http://cancer.ucsf.edu/people/profiles/cowan_morton.3548

The Genomic Landscape of Childhood Acute Lymphoblastic Leukemia

Authors*: Kathryn G. Roberts, PhD, Samuel W. Brady, PhD, Zhaohui Gu, PhD, Lei Shi, PhD, Stanley Pounds, PhD, Deqing Pei, MS, Cheng Cheng, PhD, Yunfeng Dai, PhD, Meenakshi Devidas, PhD, Chunxu Qu, PhD, Ashley Hill, Xiaotu Ma, Lei Wei, PhD, Sasi Arunachalam, PhD, Kohei Hagiwara, MD, Yangling Liu, Diane Flasch, Yu Liu, PhD, Matthew Parker, PhD, Xiaolong Chen, PhD, Yongjin Li, PhD, Yiping Fan, PhD, Robert Michael, PhD, Michael Rusch, Mark Wilkinson, Scott Foy, PhD, Dale Hedges, PhD, Scott Newman, PhD, Xin Zhou, PhD, Jian Wang, Shalini C. Reshmi, PhD, Julie M. Gastier-Foster, PhD, Patee Gesuwan, Malcolm A Smith, MD, PhD, Daniela S. Gerhard, PhD, Naomi Winick, MD, Andrew J. Carroll, PhD, Nyla A. Heerema, PhD, Richard C. Harvey, PhD, Cheryl L. Willman, MD, Eric Larsen, MD, Elizabeth A. Raetz, MD, Michael J. Borowitz, MD, PhD, Brent L. Wood, MD, PhD, William L. Carroll, MD, Patrick A. Zweidler-McKay, MD, PhD, Karen R. Rabin, MD, PhD2, Leonard A. Mattano, MD, Kelly Maloney, MD, Stuart S. Winter, MD, Michael J. Burke, MD, Wanda L. Salzer, MD, Kimberly P. Dunsmore, Anne Angiolillo, MD, Kristine R Crews, Pharm, James R. Downing, MD, Sima Jeha, MD, William E. Evans, PharmD, Ching-Hon Pui, MD, Jun J. Yang, PhD, Mary V. Relling, PharmD, Stephen P. Hunger, MD, **Mignon L. Loh, MD,** Jinghui Zhang, PhD and Charles G. Mullighan, MBBS, MD

Abstract #: 649
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper124881.html
Presentation Date/Time: Monday, December 9, 2019, 10:30 AM
Location: W224ABEF, Level 2
Presentation: Oral

Loh Research Interests: The Loh lab has focused on translating genomic and biochemical discoveries in juvenile myelomonocytic (JMML) and acute lymphoblastic leukemia (ALL) into assays and therapies that can be incorporated into clinical trials. Their work in JMML has largely focused on dissecting the genomic landscape of JMML, including descriptions of PTPN11 and CBL mutations and the discovery of CBL as a new familial tumor suppressor gene. From these discoveries, Dr. Loh established JMML CLIA molecular diagnostic testing, which is now utilized as standard testing for patients suspected of having JMML. Dr. Loh is currently Chair of the Children's Oncology Group (COG) ALL committee starting in April 2015 and responsible for supervising and implementing the next generation of national ALL trials forchildren, adolescents, and young adults.

http://cancer.ucsf.edu/people/profiles/loh_mignon.3407

Identification of New Risk Loci and Regulatory Mechanisms Influencing Genetic Susceptibility to Acute Lymphoblastic Leukaemia

Authors*: Jayaram Vijayakrishnan, Maoxiang Qian, James B. Studd, Wenjian Yang, Ben Kinnersley, Philip Law, Peter Broderick, Elizabeth A. Raetz, MD, James M. Allan, Ching-Hon Pui, MD, Ajay Vora, William E. Evans, PharmD, Anthony V. Moorman, Allen Eng Juh Yeoh, Chunliang Li, Claus Bartram, Charles G. Mullighan, MBBS, MD, Martin Zimmermann, Stephen P. Hunger, MD, Martin Schrappe, MD, PhD, Mary V. Relling, PharmD, Martin Stanulla, **Mignon L. Loh, MD,** Richard S. Houlston and Jun J. Yang, PhD

Abstract #: 650
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper125791.html
Presentation Date/Time: Monday, December 9, 2019, 10:45 AM
Location: W224ABEF, Level 2
Presentation: Oral

Loh Research Interests: The Loh lab has focused on translating genomic and biochemical discoveries in juvenile myelomonocytic (JMML) and acute lymphoblastic leukemia (ALL) into assays and therapies that can be incorporated into clinical trials. Their work in JMML has largely focused on dissecting the genomic landscape of JMML, including descriptions of PTPN11 and CBL mutations and the discovery of CBL as a new familial tumor suppressor gene. From these discoveries, Dr. Loh established JMML CLIA molecular diagnostic testing, which is now utilized as standard testing for patients suspected of having JMML. Dr. Loh is currently Chair of the Children's Oncology Group (COG) ALL committee starting in April 2015 and responsible for supervising and implementing the next generation of national ALL trials forchildren, adolescents, and young adults.

http://cancer.ucsf.edu/people/profiles/loh_mignon.3407

Acute Lymphoblastic Leukemia with Zinc-Finger Protein 384 (ZNF384)-Related Rearrangements: A Retrospective Analysis from the Ponte Di Legno Childhood ALL Working Group

Authors*: Shinsuke Hirabayashi, Ellie Butler, Kentaro Ohki, MD, PhD, Nobutaka Kiyokawa, MD, PhD, Anke K. Bergmann, Judith M. Boer, PhD, Hélène Cavé, PharmD, PhD, Giovanni Cazzaniga, Allen Eng Juh Yeoh, Toshihiko Imamura, MD, PhD, Hiroto Inaba, MD, **Mignon L. Loh, MD,** Ulrika Norén-Nyström, MD, PhD, Agata Pastorczak, Lee-Yung Shih, MD, Marketa Zaliova, MD, PhD, Oskar A Haas, Christine J. Harrison, PhD, FRCPath, Anthony V. Moorman and Atsushi Manabe, MD, PhD

Abstract #: 652
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper123236.html
Presentation Date/Time: Monday, December 9, 2019, 11:15 AM
Location: W224ABEF, Level 2
Presentation: Oral

Loh Research Interests: The Loh lab has focused on translating genomic and biochemical discoveries in juvenile myelomonocytic (JMML) and acute lymphoblastic leukemia (ALL) into assays and therapies that can be incorporated into clinical trials. Their work in JMML has largely focused on dissecting the genomic landscape of JMML, including descriptions of PTPN11 and CBL mutations and the discovery of CBL as a new familial tumor suppressor gene. From these discoveries, Dr. Loh established JMML CLIA molecular diagnostic testing, which is now utilized as standard testing for patients suspected of having JMML. Dr. Loh is currently Chair of the Children's Oncology Group (COG) ALL committee starting in April 2015 and responsible for supervising and implementing the next generation of national ALL trials forchildren, adolescents, and young adults.

http://cancer.ucsf.edu/people/profiles/loh_mignon.3407

Germline RUNX1 Variation and Predisposition to T-Cell Acute Lymphoblastic Leukemia in Children

Authors*: Yizhen Li, PhD, Maoxiang Qian, Meenakshi Devidas, PhD, Wentao Yang, PhD, Stuart S. Winter, MD, Kimberly P. Dunsmore, Colton A Smith, Ting-Nien Lin, Xuijie Zhao, Ranran Zhang, Julie M. Gastier Foster, Elizabeth A. Raetz, MD, William L. Carroll, MD, Karen R. Rabin, MD, PhD, Wenjian Yang, Patrick A. Zweidler-McKay, MD, PhD, Ching-Hon Pui, MD, William E. Evans, PharmD, Charles G. Mullighan, MBBS, MD, Stephen P. Hunger, MD, Mary V. Relling, PharmD, **Mignon L. Loh, MD** and Jun J. Yang, PhD

Abstract #: 653
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper125912.html
Presentation Date/Time: Monday, December 9, 2019, 11:30 AM
Location: W224ABEF, Level 2
Presentation: Oral

Loh Research Interests: The Loh lab has focused on translating genomic and biochemical discoveries in juvenile myelomonocytic (JMML) and acute lymphoblastic leukemia (ALL) into assays and therapies that can be incorporated into clinical trials. Their work in JMML has largely focused on dissecting the genomic landscape of JMML, including descriptions of PTPN11 and CBL mutations and the discovery of CBL as a new familial tumor suppressor gene. From these discoveries, Dr. Loh established JMML CLIA molecular diagnostic testing, which is now utilized as standard testing for patients suspected of having JMML. Dr. Loh is currently Chair of the Children's Oncology Group (COG) ALL committee starting in April 2015 and responsible for supervising and implementing the next generation of national ALL trials forchildren, adolescents, and young adults.

http://cancer.ucsf.edu/people/profiles/loh_mignon.3407

Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update

Authors*: Peter M. Voorhees, MD, Jonathan L. Kaufman, MD, Jacob P. Laubach, MD, Douglas W. Sborov, MD, Brandi Reeves, MD, Cesar Rodriguez, MD, Ajai Chari, MD, Rebecca W. Silbermann, MD, Luciano J. Costa, MD, PhD, Larry D. Anderson, MD, PhD, Nitya Nathwani, MD, **Nina D. Shah, MD,** Yvonne A. Efebera, MD, MPH, Caitlin L. Costello, MD, Andrzej Jakubowiak, MD, PhD, Tanya M Wildes, MD, Robert Z. Orlowski, MD, PHD, Kenneth H. Shain, MD, PhD, Andrew J. Cowan, MD, Sean Murphy, Yana Lutska, PharmD, Huiling Pei, PhD, Jon Ukropec, PhD, Jessica Vermeulen, MD, PhD, Carla de Boer, Daniela Hoehn, MD, PhD, Thomas S. Lin, MD, PhD and Paul G. Richardson, MD

Abstract #: 691
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper123465.html
Presentation Date/Time: Monday, December 9, 2019, 10:30 AM
Location: Hall E1, Level 2
Presentation: Oral

Shah Research Interests: Dr. Nina Shah is an expert in cellular therapy for multiple myeloma. Her research focuses on multiple myeloma clinical trials, specifically immunotherapy and cellular therapy. She performed the first-in-human clinical trial of umbilical cord blood-derived natural killer cell therapy for myeloma and is currently one of the three lead principal investigators for the multi-center BMT CTN 1401 dendritic cell vaccine trial for myeloma patients. Additionally, she is the institutional PI for numerous cellular therapy (CAR-T) and novel immunotherapy protocols at UCSF. Dr. Shah is also interested in outcomes research for myeloma patients undergoing autologous transplantation and has led a randomized trial to determine the impact of stem cell dose on symptoms in this patient population. She is currently developing a study to investigate digital life coaching during transplant recovery.

http://cancer.ucsf.edu/people/profiles/shah_nina.8258

Area-Based Socioeconomic Disparities in Survival of Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Authors*: **Lena E. Winestone, MD, MSHP,** Kelly D Getz, Kira O Bona, MD, MPH, Brian T. Fisher, DO, MSCE, Alan S. Gamis, MD, MPH, Alix E. Seif, MD, Lillian Sung, MD, PhD, Yi-Cheng Wang, Todd A. Alonzo, PhD and Richard Aplenc, MD, PhD

Abstract #: 703
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper130978.html
Presentation Date/Time: Monday, December 9, 2019, 10:30 AM
Location: Valencia D (W415D), Level 4
Presentation: Oral

Winestone Research Interests: Dr. Lena Winestone is clinically focused on pediatric blood and marrow transplant. Dr. Winestone's research explores racial, ethnic, and socioeconomic disparities in access to care and outcome of leukemia and lymphoma treatment. She has studied access to care across the continuum of cancer from diagnosis and clinical trial enrollment through treatment and relapse to salvage therapies. Her research has shown that patients from impoverished neighborhoods have inferior survival compared to those from high income neighborhoods in acute myeloid leukemia, acute lymphoid leukemia, and neuroblastoma. Her ongoing work investigates access to highly specialized and complex therapies such as stem cell transplant, chimeric antigen receptor T cells, and MIBG therapy. treatment response in patients with cancer, and especially hematologic malignancies.

http://cancer.ucsf.edu/people/profiles/winestone_lena.9218

Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia

Authors*: Kathryn E. Flynn, PhD, Kevin P. Weinfurt, PhD, Li Lin, MS, Jerald P. Radich, MD, Charles A. Schiffer, MD, Michael J. Mauro, MD, Javier Pinilla Ibarz, MD, PhD, Joseph O. Moore, MD, Richard A. Larson, MD, Vivian G. Oehler, MD, Michael W. Deininger, James E. Thompson, MD, **Neil P. Shah, MD, PhD,** Martha Wadleigh, MD, Ellen K. Ritchie, MD, Richard T. Silver, MD, Jorge E. Cortes, MD, Vamsi Kota and Ehab L. Atallah, MD

Abstract #: 705
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper126002.html
Presentation Date/Time: Monday, December 9, 2019, 11:00 AM
Location: Valencia D (W415D), Level 4
Presentation: Oral

Shah Research Interests: The Shah lab is interested in advancing targeted therapeutics for hematologic malignancies through basic studies of in vitro and in vivo model systems to gain a better understanding of the critical vulnerabilities of malignant cells, and through translational/clinical studies of samples obtained from patients participating in early phase monotherapy clinical studies to identify, validate and override mechanisms of resistance to these agents.

http://cancer.ucsf.edu/people/profiles/shah_neil.3658

Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart® Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients

Authors*: Geoffrey L. Uy, MD, Ibrahim Aldoss, MD, Matthew C. Foster, MD, David A Sallman, MD, Kendra L. Sweet, MD, David A. Rizzieri, MD, **Peter H. Sayre, MD, PhD,** Anjali S. Advani, MD, Ashkan Emadi, MD, Matthew J. Wieduwilt, MD, PhD, Norbert Vey, MD, PhD, Fabio Ciceri, MD, Matteo Giovanni Carrabba, MD, Tamara Moyo, MD, PhD, Sarah E. Church, PhD, Michael P. Rettig, PhD, Martha L. Arellano, MD, John E. Godwin, MD, Bob Löwenberg, MD, PhD, Gerwin Huls, MD, PhD, Farhad Ravandi, MD, John Muth, MS, Kathy Tran, Mojca Jongen-Lavrencic, MD, PhD, Erin Timmeny, Max S. Topp, MD, Stefania Paolini, MD, PhD, Kuo Guo, MSc, Teia Curtis, Jian Zhao, PhD, Jayakumar Vadakekolathu, PhD, Jon M. Wigginton, MD, Ezio Bonvini, MD, Sergio Rutella, MD, PhD, FRCPath, Roland B. Walter, MD, PhD, MS, Jan K. Davidson-Moncada, MD, PhD and John F. DiPersio, MD, PhD

Abstract #: 733
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper122073.html
Presentation Date/Time: Monday, December 9, 2019, 2:45 PM
Location: Tangerine 3 (WF3-4), Level 2
Presentation: Oral

Sayre Research Interests: Dr. Peter Sayre specializes in adult bone marrow transplantation and other treatments for myeloid leukemias. His research interests focus on allogeneic stem cell transplants (which use blood stem cells from a matching donor) and immunotherapy for myeloid leukemia. His work on these subjects has been published in medical and other scientific journals.

https://cancer.ucsf.edu/people/profiles/sayre_peter.6189

A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results from Children's Oncology Group Protocol AALL1621

Authors*: Maureen M. O'Brien, MD, Lingyun Ji, PhD, Nirali N. Shah, MD, Susan R. Rheingold, MD, Deepa Bhojwani, MD, Joanna S. Yi, MD, Constance M. Yuan, MD, PhD, Andrew C Harris, MD, Patrick A. Brown, MD, Michael J. Borowitz, MD, PhD, Olga Militano, PharmD, Meenakshi Devidas, PhD, Elizabeth A. Raetz, MD, Lia Gore, MD and **Mignon L. Loh, MD**

Abstract #: 741
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper128977.html
Presentation Date/Time: Monday, December 9, 2019, 3:15 PM
Location: W224CDGH, Level 2
Presentation: Oral

Loh Research Interests: The Loh lab has focused on translating genomic and biochemical discoveries in juvenile myelomonocytic (JMML) and acute lymphoblastic leukemia (ALL) into assays and therapies that can be incorporated into clinical trials. Their work in JMML has largely focused on dissecting the genomic landscape of JMML, including descriptions of PTPN11 and CBL mutations and the discovery of CBL as a new familial tumor suppressor gene. From these discoveries, Dr. Loh established JMML CLIA molecular diagnostic testing, which is now utilized as standard testing for patients suspected of having JMML. Dr. Loh is currently Chair of the Children's Oncology Group (COG) ALL committee starting in April 2015 and responsible for supervising and implementing the next generation of national ALL trials forchildren, adolescents, and young adults.

http://cancer.ucsf.edu/people/profiles/loh_mignon.3407

Paraoxonase 2 Enables Initiation of B-ALL By Subverting Metabolic Gatekeeper Functions

Authors*: Lili Pan, MD, **Chao Hong, PhD,** Gang Xiao, PhD, **Huimin Geng, PhD,** Shaoyuan Wang, MD and Markus Müschen, MD, PhD

Abstract #: 746
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper125171.html
Presentation Date/Time: Monday, December 9, 2019, 3:00 PM
Location: W224ABEF, Level 2
Presentation: Oral

Geng Research Interests: Dr. Geng's research is focused on functional genomics and epigenomics of lymphoma and leukemia using computational approaches on genome-wide array and deep sequencing data, including RNA-seq, Whole Exome-Seq, ChIP-seq, miRNA-seq and DNA methylation eRRBS-seq. Applying bioinformatic methods coupled with in vitro and in vivo experiments, they are interested in identifying and evaluating new prognostic and disease-classification biomarkers and novel therapeutic targets for different forms of lymphoma and leukemia.

http://profiles.ucsf.edu/huimin.geng

Lgr5 Functions As a Critical Negative Regulator of Wnt/β-Catenin Signaling and Is Essential for B-Lymphopoiesis and Malignant B-Cell Transformation

Authors*: Kadriye Nehir Cosgun, PhD, Gauri Deb, MS, PhD, **Xin Yang, MD,** Gang Xiao, PhD, Teresa Sadras, PhD, Jaewoong Lee, PhD, Lai N. Chan, Kohei Kume, PhD, Lu Yang, PhD, **Huimin Geng, PhD,** John Chan, MD, Joo Y. Song, MD, Hassan Jumaa, PhD, Andrew G. Polson, PhD, Hans Clevers, MD, PhD and Markus Müschen, MD, PhD

Abstract #: 748
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper127263.html
Presentation Date/Time: Monday, December 9, 2019, 3:30 PM
Location: W224ABEF, Level 2
Presentation: Oral

Geng Research Interests: Dr. Geng's research is focused on functional genomics and epigenomics of lymphoma and leukemia using computational approaches on genome-wide array and deep sequencing data, including RNA-seq, Whole Exome-Seq, ChIP-seq, miRNA-seq and DNA methylation eRRBS-seq. Applying bioinformatic methods coupled with in vitro and in vivo experiments, they are interested in identifying and evaluating new prognostic and disease-classification biomarkers and novel therapeutic targets for different forms of lymphoma and leukemia.

http://profiles.ucsf.edu/huimin.geng

Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium

Authors*: N. Nora Bennani, MD, Matthew J. Maurer, MS, Loretta J. Nastoupil, MD, MSc, Michael D. Jain, MD, PhD, Julio C. Chavez, MD, Amanda F. Cashen, MD, Saurabh Dahiya, MD, Lazaros J. Lekakis, MD, Patrick M. Reagan, MD, Olalekan O. Oluwole, MBBS, MPH, Joseph P. McGuirk, DO, Abhinav Deol, MD, Alison R. Sehgal, MD, Andre Goy, MD, Brian T. Hill, MD, **Khoan Vu, MD, Charalambos Andreadis, MD,** Javier Munoz, MD, MS, FACP, Aaron P. Rapoport, Julie M. Vose, MD MBA, David B. Miklos, MD, PhD, Frederick L. Locke, MD, Sattva S. Neelapu, MD and Yi Lin, MD, PhD

Abstract #: 763
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper129097.html
Presentation Date/Time: Monday, December 9, 2019, 2:45 PM
Location: W230, Level 2
Presentation: Oral

Andreadis Research Interests: Dr. Andreadis studies targeted therapeutics and cellular immunotherapy approaches to patients with hematologic malignancies. He is interested in the interplay of cancer genetics and pharmacogenetics as it pertains to prognosis and treatment response in patients with cancer, and especially hematologic malignancies.

http://cancer.ucsf.edu/people/profiles/andreadis_babis.3784

Breaking the Glass Ceiling of Age in Transplant in Multiple Myeloma

Authors*: Pashna N. Munshi, MD, Parameswaran Hari, MD, David H. Vesole, MD, PhD, Artur Jurczyszyn, MD, Jan Zaucha, MD PhD, Omar Davila, Shaji K. Kumar, MD, **Nina D. Shah, MD,** Muzaffar H. Qazilbash, MD and Anita D'Souza, MD, MS

Abstract #: 782
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper124804.html
Presentation Date/Time: Monday, December 9, 2019, 3:00 PM
Location: W311ABCD, Level 3
Presentation: Oral

Shah Research Interests: Dr. Nina Shah is an expert in cellular therapy for multiple myeloma. Her research focuses on multiple myeloma clinical trials, specifically immunotherapy and cellular therapy. She performed the first-in-human clinical trial of umbilical cord blood-derived natural killer cell therapy for myeloma and is currently one of the three lead principal investigators for the multi-center BMT CTN 1401 dendritic cell vaccine trial for myeloma patients. Additionally, she is the institutional PI for numerous cellular therapy (CAR-T) and novel immunotherapy protocols at UCSF. Dr. Shah is also interested in outcomes research for myeloma patients undergoing autologous transplantation and has led a randomized trial to determine the impact of stem cell dose on symptoms in this patient population. She is currently developing a study to investigate digital life coaching during transplant recovery.

http://cancer.ucsf.edu/people/profiles/shah_nina.8258

Non-Genotoxic Anti-CD117 Antibody Conditioning Results in Successful Hematopoietic Stem Cell Engraftment in Patients with Severe Combined Immunodeficiency

Authors*: Rajni Agarwal, MD, **Christopher C. Dvorak, MD,** Hye-Sook Kwon, PhD, **Janel R Long-Boyle, PharmD, PhD,** Susan S. Prohaska, PhD, MS, Janice W. Brown, MD, Anne Le, Alyssa Guttman-Klein, Irving L. Weissman, MD, **Morton J. Cowan, MD, Aaron C. Logan, MD, PhD,** Kenneth I. Weinberg, MD, Robertson Parkman, MD, Maria-Grazia Roncarolo, MD and Judith A. Shizuru, MD, PhD

Abstract #: 800
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper126239.html
Presentation Date/Time: Monday, December 9, 2019, 3:00 PM
Location: W311EFGH, Level 3
Presentation: Oral

Dvorak Research Interests: Dr. Dvorak's research interests are the supportive care aspects of pediatric hematopoietic cell transplantation (HCT), with a goal of decreasing treatment-related morbidity and mortality (especially infections), and optimizing HCT regimens for treatment of infant leukemias. Dr. Dvorak is the former Chair of the international Pediatric Blood and Marrow Transplant Consortium's (PBMTC) Supportive Care Strategy Group and Chair of the Children's Oncology Group (COG)'s Cancer Control & Supportive Care Committee. Among his clinical trials, he was the national PI of COG trial ACCL1131: An Open-Label Phase III Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections Undergoing Allogeneic HCT and the COG trial ASCT1221: A Randomized Phase II Study Comparing Two Different Conditioning Regimens Prior to Allogeneic Hematopoietic Cell Transplantation for Children with Juvenile Myelomonocytic Leukemia (JMML).

http://cancer.ucsf.edu/people/profiles/dvorak_christopher.3611

Protein Translocation Inhibitors Overcome Cytokine-Induced Glucocorticoid Resistance in T-Cell Acute Lymphoblastic Leukemia

Authors*: **Lauren K. Meyer, Cristina Delgado-Martin, PhD, Phillip P. Sharp, PhD,** Dustin McMinn, PhD, Christopher J. Kirk, PhD, **Jack Taunton, PhD and Michelle L. Hermiston, MD, PhD**

Abstract #: 805
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper127537.html
Presentation Date/Time: Monday, December 9, 2019, 4:30 PM
Location: W304ABCD, Level 3
Presentation: Oral

Hermiston Research Interests: Dr. Hermiston directs the Pediatric Immunotherapy Program. Her research interests are focused on defining the signaling networks involved in the development of lymphoid malignancies, including leukemia and lymphoma. Her team also studies how these signaling networks mediate chemotherapy resistance and how targeted therapies may restore chemosensitivity. Additionally, she is part of a team developing infrastructure for care of children with cancer in Vietnam.

http://profiles.ucsf.edu/michelle.hermiston

Delivering Intensive Therapies to Older Adults with Hematologic Malignancies: Strategies to Personalize Care

Authors*: **Rebecca L. Olin, MD MSCE**

Abstract #:
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper121168.html
Presentation Date/Time: Monday, December 9, 2019, 4:30 PM-6:00 PM
Location: W307, Level 3
Presentation: Education Program

Olin Research Interests: Dr. Rebecca Olin specializes in treating acute leukemias, myelodysplastic and myeloproliferative disorders, and aplastic anemia, as well as patients who may require bone marrow transplantation. In her research, Dr. Olin has particular interests in the treatment of older adults with blood cancers, including those undergoing bone marrow transplant. Her work focuses on the impact of patient-reported functional status on post-transplant outcomes.

http://cancer.ucsf.edu/people/profiles/olin_rebecca.3372

CAR-T Therapy - Is it Prime-Time in Myeloma?

Authors*: **Nina D. Shah, MD**

Abstract #:
Abstract link: https://ash.confex.com/ash/2019/webprogram/Session16162.html
Presentation Date/Time: Monday, December 9, 2019, 4:30 PM-6:00 PM
Location: Hall E1, Level 2
Presentation: Education Program

Shah Research Interests: Dr. Nina Shah is an expert in cellular therapy for multiple myeloma. Her research focuses on multiple myeloma clinical trials, specifically immunotherapy and cellular therapy. She performed the first-in-human clinical trial of umbilical cord blood-derived natural killer cell therapy for myeloma and is currently one of the three lead principal investigators for the multi-center BMT CTN 1401 dendritic cell vaccine trial for myeloma patients. Additionally, she is the institutional PI for numerous cellular therapy (CAR-T) and novel immunotherapy protocols at UCSF. Dr. Shah is also interested in outcomes research for myeloma patients undergoing autologous transplantation and has led a randomized trial to determine the impact of stem cell dose on symptoms in this patient population. She is currently developing a study to investigate digital life coaching during transplant recovery.

http://cancer.ucsf.edu/people/profiles/shah_nina.8258

Excellent Outcomes with Reduced Frequency of Vincristine and Dexamethasone Pulses in Children with National Cancer Institute (NCI) Standard-Risk B Acute Lymphoblastic Leukemia (SR B-ALL): A Report from Children's Oncology Group (COG) Study AALL0932

Authors*: Anne Angiolillo, MD, Reuven J. Schore, MD, John Kairalla, Meenakshi Devidas, Karen R. Rabin, MD, PhD, Patrick A. Zweidler-McKay, MD, PhD, Michael J. Borowitz, MD, PhD, Brent L. Wood, MD, PhD, Andrew J. Carroll, PhD, Nyla A. Heerema, PhD, Mary V. Relling, PharmD, Ashley Lane, Kelly Maloney, MD, Cindy Wang, MS, William L. Carroll, MD, Naomi Winick, MD, Elizabeth A. Raetz, MD, **Mignon L. Loh, MD** and Stephen P. Hunger, MD

Abstract #: 824
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper123565.html
Presentation Date/Time: Monday, December 9, 2019, 4:45 PM
Location: Tangerine 1 (WF1), Level 2
Presentation: Oral

Loh Research Interests: The Loh lab has focused on translating genomic and biochemical discoveries in juvenile myelomonocytic (JMML) and acute lymphoblastic leukemia (ALL) into assays and therapies that can be incorporated into clinical trials. Their work in JMML has largely focused on dissecting the genomic landscape of JMML, including descriptions of PTPN11 and CBL mutations and the discovery of CBL as a new familial tumor suppressor gene. From these discoveries, Dr. Loh established JMML CLIA molecular diagnostic testing, which is now utilized as standard testing for patients suspected of having JMML. Dr. Loh is currently Chair of the Children's Oncology Group (COG) ALL committee starting in April 2015 and responsible for supervising and implementing the next generation of national ALL trials forchildren, adolescents, and young adults.

http://cancer.ucsf.edu/people/profiles/loh_mignon.3407

Ezh1 Inhibits Commitment to Hemogenic Fate and HSPC Formation during Vertebrate Development

Authors*: Rebecca Soto, Edroaldo Lummertz da rocha, PhD, **Linda T. Vo, PhD,** Mariam Hachimi, PhD, Jenna M. Frame, PhD, Paul J. Wrighton, PhD, Wolfram Goessling, MD, PhD, George Q. Daley, MD, PhD and Trista E. North, PhD

Abstract #: 3710
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper131464.html
Presentation Date/Time: Monday, December 9, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

Vo Research Interests: My research career is focused on the development of novel prognostic and predictive biomarkers and incorporation of these biomarkers into new clinical trials, working towards more effective and less toxic therapies in children and young adults with solid tumors.

http://cancer.ucsf.edu/people/profiles/vo_kieuhoa.7395

Targeting Unique Synthetic Lethal Interactions between PI3K and MYC in B-ALL

Authors*: Gang Xiao, PhD, Kohei Kume, PhD, **Huimin Geng, PhD,** Than Than Han, MS, Lars Klemm, MS and Markus Müschen, MD, PhD

Abstract #: 3785
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper128719.html
Presentation Date/Time: Monday, December 9, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

Geng Research Interests: Dr. Geng's research is focused on functional genomics and epigenomics of lymphoma and leukemia using computational approaches on genome-wide array and deep sequencing data, including RNA-seq, Whole Exome-Seq, ChIP-seq, miRNA-seq and DNA methylation eRRBS-seq. Applying bioinformatic methods coupled with in vitro and in vivo experiments, they are interested in identifying and evaluating new prognostic and disease-classification biomarkers and novel therapeutic targets for different forms of lymphoma and leukemia.

http://profiles.ucsf.edu/huimin.geng

Blinatumomab in Combination with Pembrolizumab Is Safe for Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: University of California Hematologic Malignancies Consortium Study 1504

Authors*: Marc Schwartz, MD, **Lloyd E. Damon, MD,** Deepa Jeyakumar, MD, Caitlin L. Costello, MD, Dimitrios Tzachanis, MD, PhD, Gary J. Schiller, MD, Jesika Reiner, MPH and Matthew J. Wieduwilt, MD, PhD

Abstract #: 3880
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper131061.html
Presentation Date/Time: Monday, December 9, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Authors*: Courtney D. DiNardo, MD, MSc, **Rebecca Olin, MD, MSCE,** Jo Ishizawa, MD, PhD, Hiroyuki Sumi, PhD, Jingdong Xie, PhD, Kazunobu Kato, MD, PhD, Prasanna Kumar, PhD and Michael Andreeff, MD, PhD

Abstract #: 3932
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper122241.html
Presentation Date/Time: Monday, December 9, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

Olin Research Interests: Dr. Rebecca Olin specializes in treating acute leukemias, myelodysplastic and myeloproliferative disorders, and aplastic anemia, as well as patients who may require bone marrow transplantation. In her research, Dr. Olin has particular interests in the treatment of older adults with blood cancers, including those undergoing bone marrow transplant. Her work focuses on the impact of patient-reported functional status on post-transplant outcomes.

http://cancer.ucsf.edu/people/profiles/olin_rebecca.3372

Signaling Input from Divergent Pathways Subverts Malignant B-Cell Transformation

Authors*: Lai N Chan, Mark A. Murakami, MD, MA, MMSc, Rebecca Caesar, Christian Hurtz, PhD, Kohei Kume, PhD, Teresa Sadras, PhD, **Seyedmehdi Shojaee, PhD,** Petri Pölönen, MSc, Amol Ugale, PhD, Jaewoong Lee, PhD, Kadriye Nehir Cosgun, PhD, **Huimin Geng, PhD,** Merja Heinäniemi, PhD, Olli Lohi, MD, PhD, **Arun P. Wiita, MD, PhD,** Shai Izraeli, MD, David M Weinstock and Markus Müschen, MD, PhD

Abstract #: 3944
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper130774.html
Presentation Date/Time: Monday, December 9, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

Wiita Research Interests: The Wiita Lab uses a combination of genome engineering, chemical biology, bioinformatics, and quantitative mass spectrometry-based proteomics to discover basic biology and new therapeutic targets in hematologic malignancies. Particular interests include mechanisms of resistance to small molecule and immunotherapy agents, and new strategies to overcome resistance. Significant effort is being devoted to using cell surface proteomics to identify alterations in cell-surface antigens enriched in poor-prognosis settings, combined with nanobody engineering to develop novel cellular therapies to target these disease states. In addition, the Wiita Lab also includes the Stephen and Nancy Grand Multiple Myeloma Translational Initiative (MMTI) laboratory. The MMTI Lab works with academic and industry partners to perform preclinical evaluation of new small molecules and immunotherapies across a suite of in vitro, in vivo, and patient ex vivo models, with the goal of moving compounds into the clinic.

https://wiitalab.ucsf.edu

RUNX2 Regulates Cell Migration in T-Cell Lineage Acute Lymphoblastic Leukemia

Authors*: Nitesh Devinarayan Sharma, PhD, Christian C. Nickl, Huining Kang, PhD, Wojciech Ornatowski, PhD, Stuart S. Winter, MD, **Mignon L. Loh, MD,** Stephen P. Hunger, MD and Ksenia Matlawska-Wasowska, PhD

Abstract #: 3947
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper129337.html
Presentation Date/Time: Monday, December 9, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

Loh Research Interests: The Loh lab has focused on translating genomic and biochemical discoveries in juvenile myelomonocytic (JMML) and acute lymphoblastic leukemia (ALL) into assays and therapies that can be incorporated into clinical trials. Their work in JMML has largely focused on dissecting the genomic landscape of JMML, including descriptions of PTPN11 and CBL mutations and the discovery of CBL as a new familial tumor suppressor gene. From these discoveries, Dr. Loh established JMML CLIA molecular diagnostic testing, which is now utilized as standard testing for patients suspected of having JMML. Dr. Loh is currently Chair of the Children's Oncology Group (COG) ALL committee starting in April 2015 and responsible for supervising and implementing the next generation of national ALL trials forchildren, adolescents, and young adults.

http://cancer.ucsf.edu/people/profiles/loh_mignon.3407

Report on the Treatment of Hodgkin Lymphoma with ABVD Chemotherapy at Two Rural District Hospitals in Rwanda

Authors*: Cyprien Shyirambere, MD, **Rebecca Deboer, MD,** Yvan Butera, MD, Caitlin Driscoll, Jean Bosco Bigirimana, Francois Regis Uwizeye, Temidayo Fadelu, MD, Paul H. Park, MD, **Alan Paciorek,** Leslie E. Lehmann, MD and Lawrence N. Shulman, MD

Abstract #: 4053
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper130780.html
Presentation Date/Time: Monday, December 9, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)

Authors*: Pau Abrisqueta, MD, PhD, Juan-Manuel Sancho, MD, PhD, Raul Cordoba, MD, PhD, Daniel O. Persky, MD, C**haralambos Andreadis, MD, MSCE,** Scott F. Huntington, MD, MPH, Cecilia Carpio, MD, Daniel Morillo Giles, MD, Xin Wei, PhD, Ying Fei Li, PhD, Marlene Zuraek, MD, Michael R. Burgess, Kristen Hege and Alejandro Martín, MD, PhD

Abstract #: 4089
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper125310.html
Presentation Date/Time: Monday, December 9, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

Andreadis Research Interests: Dr. Andreadis studies targeted therapeutics and cellular immunotherapy approaches to patients with hematologic malignancies. He is interested in the interplay of cancer genetics and pharmacogenetics as it pertains to prognosis and treatment response in patients with cancer, and especially hematologic malignancies.

http://cancer.ucsf.edu/people/profiles/andreadis_babis.3784

Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial

Authors*: Jason R. Westin, MD, Constantine S. Tam, MBBS, MD, Peter Borchmann, Ulrich Jaeger, MD, Joseph P. McGuirk, DO, Harald Holte, MD, PhD, Edmund K. Waller, PhD, MD, Samantha Jaglowski, MD, MPH, Michael R. Bishop, MD, C**haralambos Andreadis, MD, MSCE,** Stephen Ronan Foley, MD, FRCPC, Isabelle Fleury, MD, P Joy Ho, MBBS(Syd) DPhil(Oxon) FRACP FRCPA FFSc(RCPA), Stephan Mielke, MD, Takanori Teshima, MD, Stephen J. Schuster, MD, Veronika Bachanova, MD, PhD, Richard T. Maziarz, MD, Koen Van Besien, MD, PhD, Koji Izutsu, MD, PhD, Marie Jose Kersten, MD, PhD, John M. Magenau, MD, Nina D. Wagner-Johnston, MD, Koji Kato, MD, PhD, Paolo Corradini, Xia Han, MS, Ranjan Tiwari, MSc, Sergei Agoulnik, PhD, Lamis K. Eldjerou, MD, Lida Bubuteishvili Pacaud, MD and Gilles A. Salles, MD, PhD

Abstract #: 4103
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper129107.html
Presentation Date/Time: Monday, December 9, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

Andreadis Research Interests: Dr. Andreadis studies targeted therapeutics and cellular immunotherapy approaches to patients with hematologic malignancies. He is interested in the interplay of cancer genetics and pharmacogenetics as it pertains to prognosis and treatment response in patients with cancer, and especially hematologic malignancies.

http://cancer.ucsf.edu/people/profiles/andreadis_babis.3784

Highly Favorable Outcomes with Salvage Radiation Therapy Followed By Autologous Transplant in Relapsed and Refractory DLBCL Patients with Minimal or No Response to Salvage Chemotherapy

Authors*: **Joanna C. Yang, MD, MPH,** Karen Chau, Michael Scordo, MD, Craig S. Sauter, MD and Joachim Yahalom, MD

Abstract #: 4137
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper131664.html
Presentation Date/Time: Monday, December 9, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

Association of High Body Mass Index with Response Outcomes in Patients with CML-CP Treated with Dasatinib Versus Imatinib in the First Line: Exploratory Post Hoc Analysis of the Phase 3 DASISION Trial

Authors*: Massimo Breccia, MD, Jorge E. Cortes, MD, **Neil P Shah, MD, PhD,** Giuseppe Saglio, MD, Antonio Jiménez-Velasco, MD, Philipp Le Coutre, MD, Alexander Brun, PharmD, Irene DeGutis, Sai Bathena, Oumar Sy, PhD and Elias Jabbour

Abstract #: 4155
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper121872.html
Presentation Date/Time: Monday, December 9, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

Shah Research Interests: The Shah lab is interested in advancing targeted therapeutics for hematologic malignancies through basic studies of in vitro and in vivo model systems to gain a better understanding of the critical vulnerabilities of malignant cells, and through translational/clinical studies of samples obtained from patients participating in early phase monotherapy clinical studies to identify, validate and override mechanisms of resistance to these agents.

http://cancer.ucsf.edu/people/profiles/shah_neil.3658

Association between a Polygenic Risk Score for Multiple Myeloma Risk and Overall Survival

Authors*: Jonathan N. Hofmann, PhD, John Spinelli, PhD, MSc, Graham Giles, Parveen Bhatti, PhD, Wendy Cozen, DO, MPH, Dennis P. Robinson, Daniel R O'Brien, S. Vincent Rajkumar, MD, Shulan Tian, MS, PhD, Sonja I. Berndt, PhD, Stephen J. Chanock, MD, Mitchell Machiela, PhD, Aaron D. Norman, Jason P. Sinnwell, MS, Xifeng Wu, PhD, Rosalie Griffin Waller, Roger L. Milne, BCom, BSW, BA, Grad Dip Clinical Epi, MSc, PhD, Susan L. Slager, PhD, Shaji K. Kumar, MD, Nicola J. Camp, PhD, **Elad Ziv, MD** and Celine M. Vachon, PhD

Abstract #: 4366
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper126088.html
Presentation Date/Time: Monday, December 9, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

Ziv Research Interests: Dr. Ziv's group focuses on understanding how inherited genetic variation affects cancer risk, progression and response to therapy. A major interest has been genetic susceptibility to breast cancer among Latinas. They use a variety of methods including admixture analysis, genome wide association and whole exome sequencing approach to study breast cancer risk among Latinas. They are also studying germline-somatic interactions in breast tumors from Latina women. In addition, they are interested in how genetic variation affects the immune response to tumors and are studying germline variation as a predictor of response and adverse events from immunotherapy. They are also working on studies of the genetics underlying multiple myeloma susceptibility and progression.

http://cancer.ucsf.edu/people/profiles/ziv_elad.3779

Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans

Authors*: **Linda Kachuri, PhD, MPH,** Zhaohui Du, MS, Niels Weinhold, PhD, Gregory Song, Kristin Alyse Rand, PhD, MPH, David Van Den Berg, PhD, Amie Hwang, PhD, MPH, Xin Sheng, MS, Victor Hom, MS, Sikander Ailawadhi, MD, Ajay K. Nooka, MD, Seema Singhal, MD, Edward S. Peters, DMD, SM, SM, ScD, Cathryn Bock, PhD, Ann Mohrbacher, MD, Alexander Stram, MS, Sonja I. Berndt, PhD, William J. Blot, PhD, Esther M. John, Leslie Bernstein, PhD, MS, Antoinette Stroup, PhD, Maurizio Zangari, MD, Frits van Rhee, MD, PhD, Andrew Olshan, Wei Zheng, MD, PhD, Sue Ann Ingles, PhD, Michael Press, PhD/MD, John David Carpten, PhD, Stephen J. Chanock, MD, Jayesh Mehta, MD, Graham A. Colditz, MD, DrPH, **Jeffrey Wolf, MD, Thomas G. Martin III, MD,** Mark A. Fiala, Howard R. Terebelo, DO, Nalini Janakiraman, MD, Laurence Kolonel, MD, PhD, Kenneth C. Anderson, MD, Loic Le Marchand, MD, PhD, Daniel Auclair, Brian C.-H. Chiu, PhD, Daniel Stram, PhD, Ravi Vij, MBBS, Leon Bernal-Mizrachi, MD, Gareth Morgan, MD, PhD, Jeffrey A. Zonder, MD, Carol Ann Huff, MD, Sagar Lonial, MD, Robert Z. Orlowski, MD, PhD, David Conti, PhD, Christopher A. Haiman, PhD, **Elad Ziv, MD, John S. Witte, PhD** and Wendy Cozen, DO, MPH

Abstract #: 4379
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper129298.html
Presentation Date/Time: Monday, December 9, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

Witte Research Interests: Our research program encompasses a synthesis of methodological and applied genetic epidemiology, with the overall aim of deciphering the mechanisms underlying complex diseases and traits (Witte, Visscher & Wray, Nature Reviews Genetics 2014). Our methods work is focused on the design and statistical analysis of next-generation sequencing and genetic association studies. We are applying these methods to studies of cancer (e.g., of the prostate), birth defects, and pharmacogenomics.

http://wittelab.ucsf.edu

Characterization of Monoclonal Gammopathy of Undetermined Significance Progression to Multiple Myeloma through Meta-Analysis of GEO Data

Authors*: Jihad Aljabban, MMSc, David Chen, Francesca Cottini, MD, Saad Syed, Nabeal Aljabban, Sharjeel Syed, Tiffany Hughes, PhD, David Feldman, **Dexter Hadley, MD, PhD** and Don M. Benson Jr., MD, PhD

Abstract #: 4395
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper129699.html
Presentation Date/Time: Monday, December 9, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

Hadley Research Interests: Dr. Hadley's expertise is in translating big data into precision medicine and digital health. His research generates, annotates, and ultimately reasons over large multi-modal data stores to identify novel biomarkers and potential therapeutics for disease. His early work resulted in a successful precision medicine clinical trial for ADHD a first-in-class, non-stimulant neuromodulator to be targeted across the neuropsychiatric disease spectrum. More recently, his laboratory was funded by the NIH Big Data to Knowledge initiative to develop the stargeo.org online portal to crowdsource annotations of open genomics big data that allows users to discover the functional genes and biological pathways that are defective in disease. Dr. Hadley also develops state-of-the-art data driven models of clinical intelligence that drive clinical applications to more precisely screen, diagnose, and manage disease. The end point of his work is rapid proofs of concept clinical trials in humans that translate into better patient outcomes and reduced morbidity and mortality across the spectrum of disease.

http://cancer.ucsf.edu/people/profiles/hadley_dexter.8139

Germline Variation Predicts Treatment Response in Multiple Myeloma

Authors*: **Kyle Roter, Donglei Hu, PhD,** Alyssa Clay-Gilmour, PhD, **Scott Huntsman, Nina D. Shah, MD, Sandy W. Wong, MD, Thomas G. Martin III, MD, Jeffrey Lee Wolf, MD,** Moritz Binder, MD, MPH, Shaji K. Kumar, MD, S. Vincent Rajkumar, MD, Susan L. Slager, PhD, Celine M. Vachon, PhD and **Elad Ziv, MD**

Abstract #: 4397
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper129344.html
Presentation Date/Time: Monday, December 9, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

Ziv Research Interests: Dr. Ziv's group focuses on understanding how inherited genetic variation affects cancer risk, progression and response to therapy. A major interest has been genetic susceptibility to breast cancer among Latinas. They use a variety of methods including admixture analysis, genome wide association and whole exome sequencing approach to study breast cancer risk among Latinas. They are also studying germline-somatic interactions in breast tumors from Latina women. In addition, they are interested in how genetic variation affects the immune response to tumors and are studying germline variation as a predictor of response and adverse events from immunotherapy. They are also working on studies of the genetics underlying multiple myeloma susceptibility and progression.

http://cancer.ucsf.edu/people/profiles/ziv_elad.3779

A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in Combination with Daratumumab As a Salvage Regimen for Multiple Myeloma

Authors*: **Nina D. Shah, MD,** Cameron J. Turtle, MBBS, PhD, Andrew J. Cowan, MD, Julio C. Chavez, MD, Lihua E Budde, MD, PhD, Mario Q. Marcondes, MD, PhD, Zachary Lee, PharmD, Wei Lin, MD, Jonathan Zalevsky, Mary Tagliaferri, MD and Krina K. Patel, MD, MSc

Abstract #: 4459
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper122494.html
Presentation Date/Time: Monday, December 9, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

Shah Research Interests: Dr. Nina Shah is an expert in cellular therapy for multiple myeloma. Her research focuses on multiple myeloma clinical trials, specifically immunotherapy and cellular therapy. She performed the first-in-human clinical trial of umbilical cord blood-derived natural killer cell therapy for myeloma and is currently one of the three lead principal investigators for the multi-center BMT CTN 1401 dendritic cell vaccine trial for myeloma patients. Additionally, she is the institutional PI for numerous cellular therapy (CAR-T) and novel immunotherapy protocols at UCSF. Dr. Shah is also interested in outcomes research for myeloma patients undergoing autologous transplantation and has led a randomized trial to determine the impact of stem cell dose on symptoms in this patient population. She is currently developing a study to investigate digital life coaching during transplant recovery.

http://cancer.ucsf.edu/people/profiles/shah_nina.8258

Reduced Toxicity Conditioning for Non-Malignant Hematopoietic Cell Transplants

Authors*: Cristina F Contreras Burrola, **Janel R. Long-Boyle, PharmD, PhD, Kristin A. Shimano, MD, Jasmeen Dara, MD, James N. Huang, MD, Sandhya Kharbanda, MD, Alexis Melton, MD, PhD, Christine Higham, MD, Morton J. Cowan, MD and Christopher C. Dvorak, MD**

Abstract #: 4481
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper127218.html
Presentation Date/Time: Monday, December 9, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

Dvorak Research Interests: Dr. Dvorak's research interests are the supportive care aspects of pediatric hematopoietic cell transplantation (HCT), with a goal of decreasing treatment-related morbidity and mortality (especially infections), and optimizing HCT regimens for treatment of infant leukemias. Dr. Dvorak is the former Chair of the international Pediatric Blood and Marrow Transplant Consortium's (PBMTC) Supportive Care Strategy Group and Chair of the Children's Oncology Group (COG)'s Cancer Control & Supportive Care Committee. Among his clinical trials, he was the national PI of COG trial ACCL1131: An Open-Label Phase III Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections Undergoing Allogeneic HCT and the COG trial ASCT1221: A Randomized Phase II Study Comparing Two Different Conditioning Regimens Prior to Allogeneic Hematopoietic Cell Transplantation for Children with Juvenile Myelomonocytic Leukemia (JMML).

http://cancer.ucsf.edu/people/profiles/dvorak_christopher.3611

Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials

Authors*: Polina Shindiapina, MD, PhD, Maciej Pietrzak, PhD, Michal Seweryn, PhD, Eric McLaughlin, MS, Xiaoli Zhang, PhD, Mateusz Makowski, PhD, Justin Lyberger, Hsiaochi Chang, Elshafa Hassan Ahmed, DVM, PhD, Alexander Prouty, Rebecca Pearson, Rhonda Kitzler, Jennifer Le-Rademacher, PhD, Richard F. Little, MD, MPH, Gorgun Akpek, MD, Ernesto Ayala, MD, Steven Devine, MD, Ariela Noy, MD, **Lawrence D Kaplan, MD,** Uday Popat, MD, Jack W. Hsu, MD, Lawrence E Morris, MD, Adam M. Mendizabal, MS, Craig C. Hofmeister, MD, MPH, William Wachsman, MD, PhD, Stephen J. Forman, MD, Willis H. Navarro, MD, Joseph C. Alvarnas, MD, Richard F. Ambinder, MD, Gregory K. Behbehani, MD, PhD, Gerard Lozanski, MD and Robert A. Baiocchi, MD, PhD

Abstract #: 4525
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper129488.html
Presentation Date/Time: Monday, December 9, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

Cognitive Impairment Is Associated with Inferior Survival and Increased Non-Relapse Mortality in Older Allogeneic Hematopoietic Cell Transplant (alloHCT) Recipients: A Multicenter Retrospective Study

Authors*: **Rebecca L. Olin, MD MSCE,** Caitrin Fretham, Marcelo C. Pasquini, MD, Mukta Arora, MD, Vijaya R. Bhatt, MD, Benjamin Derman, MD, BA, Sergio A. Giralt, MD, **Li-Wen Huang, MD,** Thuy T. Koll, MD, Sang Mee Lee, PHD, Richard J. Lin, MD, PhD, Linda Pang, MD, Uday Popat, MD, Daniel J. Weisdorf, MD and Andrew S. Artz, MD

Abstract #: 4606
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper123598.html
Presentation Date/Time: Monday, December 9, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

Olin Research Interests: Dr. Rebecca Olin specializes in treating acute leukemias, myelodysplastic and myeloproliferative disorders, and aplastic anemia, as well as patients who may require bone marrow transplantation. In her research, Dr. Olin has particular interests in the treatment of older adults with blood cancers, including those undergoing bone marrow transplant. Her work focuses on the impact of patient-reported functional status on post-transplant outcomes.

http://cancer.ucsf.edu/people/profiles/olin_rebecca.3372

Next Generation Sequence Minimal Residual Disease (NGS-MRD) Predicts Outstanding Event Free Survival (EFS) Regardless of Hematopoietic Cell Transplantation (HCT) Preparative Approach or Graft Alpha/Beta Depletion in Children with Acute Lymphoblastic Leukemia (ALL)

Authors*: Hisham Abdel-Azim, **Christopher C. Dvorak, MD,** Nancy Bunin, MD, Mark C. Walters, MD, Julie-An Talano, MD, Eric Jon Anderson, MD, Jemily Malvar, MS, May Al Jassani, Sonali Chaudhury, MBBS, MD, Mitchell S. Cairo, MD, Carrie Kitko, MD, Allison P. Jacob, Dimitri S. Monos, PhD, Leung Wing, MD, PhD and Michael A. Pulsipher, MD

Abstract #: 4624
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper131706.html
Presentation Date/Time: Monday, December 9, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

Dvorak Research Interests: Dr. Dvorak's research interests are the supportive care aspects of pediatric hematopoietic cell transplantation (HCT), with a goal of decreasing treatment-related morbidity and mortality (especially infections), and optimizing HCT regimens for treatment of infant leukemias. Dr. Dvorak is the former Chair of the international Pediatric Blood and Marrow Transplant Consortium's (PBMTC) Supportive Care Strategy Group and Chair of the Children's Oncology Group (COG)'s Cancer Control & Supportive Care Committee. Among his clinical trials, he was the national PI of COG trial ACCL1131: An Open-Label Phase III Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections Undergoing Allogeneic HCT and the COG trial ASCT1221: A Randomized Phase II Study Comparing Two Different Conditioning Regimens Prior to Allogeneic Hematopoietic Cell Transplantation for Children with Juvenile Myelomonocytic Leukemia (JMML).

http://cancer.ucsf.edu/people/profiles/dvorak_christopher.3611

Incidence and Cost of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with and without Multi-Organ Dysfunction: Analysis of the Premier Healthcare Database

Authors*: **Christopher C. Dvorak, MD,** Zhun Cao, PhD, Kwanza Price, MPH, JeanPierre Coaquira, Craig Lipkin, Scott Robinson and Partow Kebriaei, MD

Abstract #: 4706
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper123499.html
Presentation Date/Time: Monday, December 9, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

Dvorak Research Interests: Dr. Dvorak's research interests are the supportive care aspects of pediatric hematopoietic cell transplantation (HCT), with a goal of decreasing treatment-related morbidity and mortality (especially infections), and optimizing HCT regimens for treatment of infant leukemias. Dr. Dvorak is the former Chair of the international Pediatric Blood and Marrow Transplant Consortium's (PBMTC) Supportive Care Strategy Group and Chair of the Children's Oncology Group (COG)'s Cancer Control & Supportive Care Committee. Among his clinical trials, he was the national PI of COG trial ACCL1131: An Open-Label Phase III Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections Undergoing Allogeneic HCT and the COG trial ASCT1221: A Randomized Phase II Study Comparing Two Different Conditioning Regimens Prior to Allogeneic Hematopoietic Cell Transplantation for Children with Juvenile Myelomonocytic Leukemia (JMML).

http://cancer.ucsf.edu/people/profiles/dvorak_christopher.3611

Health Care Costs Associated with Contemporary Chronic Myelogenous Leukemia (CML) Therapy Compared to Other Hematologic Malignancies (HEM)

Authors*: Jennifer J. Wilkes, MD MSCE, Gary H. Lyman, MD, David R Doody, MS, Shasank R. Chennupati, PharmD, MPH, Laura Becker, MS, Pamela E. Morin, **Lena E. Winestone, MD, MSHP,** Henry (Joe) Henk, PhD and Eric J. Chow, MD, MPH

Abstract #: 4753
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper124106.html
Presentation Date/Time: Monday, December 9, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

Winestone Research Interests: Dr. Lena Winestone is clinically focused on pediatric blood and marrow transplant. Dr. Winestone's research explores racial, ethnic, and socioeconomic disparities in access to care and outcome of leukemia and lymphoma treatment. She has studied access to care across the continuum of cancer from diagnosis and clinical trial enrollment through treatment and relapse to salvage therapies. Her research has shown that patients from impoverished neighborhoods have inferior survival compared to those from high income neighborhoods in acute myeloid leukemia, acute lymphoid leukemia, and neuroblastoma. Her ongoing work investigates access to highly specialized and complex therapies such as stem cell transplant, chimeric antigen receptor T cells, and MIBG therapy.

http://cancer.ucsf.edu/people/profiles/winestone_lena.9218

Factors Associated with Risk and Prognosis of Intensive Care Unit Admission in Patients with Acute Myeloid Leukemia: A Danish Nationwide Cohort Study

Authors*: Cecilie Velsoe Maeng, Christian Fynbo Christiansen, MD, PhD, **Kathleen Dori Liu, MD, PhD** and Lene Sofie Granfeldt Oestgaard, MD, PhD

Abstract #: 4783
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper123254.html
Presentation Date/Time: Monday, December 9, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

Liu Research Interests: My current research areas of interest focus on the predictive and pathogenetic role of biomarkers for both acute and chronic disease states. My long term goal is to identify and validate novel biomarkers of organ injury (specifically, the kidney and lung) that may have predictive value for disease outcomes as well as shed important insight into disease pathogenesis. In addition, I have a major interest in clinical trials in the Intensive Care Unit, with a particular focus on acute lung injury and acute kidney injury.

https://profiles.ucsf.edu/kathleen.liu

Ten Years of Treating Chronic Myeloid Leukemia in Rural Rwanda: Feasible Approaches for Low-Resource Settings

Authors*: Jennifer Morgan, MD, Jean Bosco Bigirimana, Cam Nguyen, MSPH, **Rebecca Deboer, MD,** Cyprien Shyirambere, MD, **Alan Paciorek,** Leslie E. Lehmann, MD and Lawrence N. Shulman, MD

Abstract #: 4788
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper126152.html
Presentation Date/Time: Monday, December 9, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2
Presentation: Poster

Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy

Authors*: Jesus G. Berdeja, MD, Melissa Alsina, MD, **Nina D. Shah, MD,** David S. Siegel, Sundar Jagannath, MD, Deepu Madduri, MD, Jonathan L. Kaufman, MD, Nikhil C Munshi, MD, Jacalyn Rosenblatt, MD, Jagoda K. Jasielec, MD, Yi Lin, MD, PhD, Ashley Turka, Lyh Ping Lam, PharmD, RPh, Monica Massaro, MPH, Timothy B. Campbell, MD, PhD, Kristen Hege, Fabio Petrocca, MD and Noopur S. Raje, MD

Abstract #: 927
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper126660.html
Presentation Date/Time: Monday, December 9, 2019, 6:45 PM
Location: Valencia A (W415A), Level 4
Presentation: Oral

Shah Research Interests: Dr. Nina Shah is an expert in cellular therapy for multiple myeloma. Her research focuses on multiple myeloma clinical trials, specifically immunotherapy and cellular therapy. She performed the first-in-human clinical trial of umbilical cord blood-derived natural killer cell therapy for myeloma and is currently one of the three lead principal investigators for the multi-center BMT CTN 1401 dendritic cell vaccine trial for myeloma patients. Additionally, she is the institutional PI for numerous cellular therapy (CAR-T) and novel immunotherapy protocols at UCSF. Dr. Shah is also interested in outcomes research for myeloma patients undergoing autologous transplantation and has led a randomized trial to determine the impact of stem cell dose on symptoms in this patient population. She is currently developing a study to investigate digital life coaching during transplant recovery.

http://cancer.ucsf.edu/people/profiles/shah_nina.8258

TUESDAY, DECEMBER 10, 2019

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331

Authors*: Patrick A. Brown, MD, Lingyun Ji, PhD, Xinxin Xu, MS, Meenakshi Devidas, PhD, Laura Hogan, MD, Michael J. Borowitz, MD, PhD, Elizabeth A. Raetz, MD, Gerhard Zugmaier, Elad Sharon, MD, MPH, Lia Gore, MD, James A. Whitlock, MD, Michael A. Pulsipher, MD, Stephen P. Hunger, MD and **Mignon L. Loh, MD**

Abstract #: LBA-1
Abstract link: https://ash.confex.com/ash/2019/webprogram/Paper132435.html
Presentation Date/Time: Tuesday, December 10, 2019, 7:30 AM-9:00 AM
Location: Hall D, Level 2
Presentation: Late-Breaking Abstracts Session

Loh Research Interests: The Loh lab has focused on translating genomic and biochemical discoveries in juvenile myelomonocytic (JMML) and acute lymphoblastic leukemia (ALL) into assays and therapies that can be incorporated into clinical trials. Their work in JMML has largely focused on dissecting the genomic landscape of JMML, including descriptions of PTPN11 and CBL mutations and the discovery of CBL as a new familial tumor suppressor gene. From these discoveries, Dr. Loh established JMML CLIA molecular diagnostic testing, which is now utilized as standard testing for patients suspected of having JMML. Dr. Loh is currently Chair of the Children's Oncology Group (COG) ALL committee starting in April 2015 and responsible for supervising and implementing the next generation of national ALL trials forchildren, adolescents, and young adults.

http://cancer.ucsf.edu/people/profiles/loh_mignon.3407

SUMMARY OF ABSTRACTS BY FACULTY MEMBER

Adam Abate, PhD

2088 Combined Single-Cell DNA Genotyping and Protein Quantification (DAb-seq) in Acute Myeloid Leukemias Reveals Distinct Immunophenotypic Subsets Among Pathogenic Clones

Weiyung Z. Ai, MD, PhD

1578 Development of a Pathway-Directed Drug Screen Platform for Cutaneous T Cell Lymphoma Using Patient-Derived Xenograft Models

Charalambos (Babis) Andreadis, MD, MSCE

241 Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas

242 Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL)

245 Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium

1583 Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium

2828 A Phase 1b Dose Escalation Trial of Carfilzomib in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

2855 Current Selection Patterns, Toxicities and Outcomes of Pre-Transplant Salvage Treatment Regimens in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of a Multicenter Retrospective Analysis

2868 Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Ineligible Patients: Transcend NHL 001, Outreach, and PILOT

2883 Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel

763 Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium

4089 Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)

4103 Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial

Morton J. Cowan, MD

2058 Lentiviral Gene Therapy with Low Dose Busulfan for Infants with X-SCID Results in the Development of a Functional Normal Immune System: Interim Results of an Ongoing Phase I/II Clinical Study

608 Enhanced Transduction Lentivector Gene Therapy for Treatment of Older Patients with X-Linked Severe Combined Immunodeficiency

Lloyd E. Damon, MD

3880 Blinatumomab in Combination with Pembrolizumab Is Safe for Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: University of California Hematologic Malignancies Consortium Study 1504

Aditi Dasgupta, MD

3383 A Clinical Pathway Reduces Admissions for Vaso-Occlusive Pain in Sickle Cell Disease

Wiliam F. DeGrado, PhD

2344 Direct Visualization of Platelet Integrins Using ANTI-Transmembrane Domain Peptides Containing a BLUE Fluorescent Amino Acid

Christopher C. Dvorak, MD

3343 Role of Disease Mechanism in Hematopoietic Cell Transplantation Outcomes for Hemophagocytic Lymphohistiocytosis

800 Non-Genotoxic Anti-CD117 Antibody Conditioning Results in Successful Hematopoietic Stem Cell Engraftment in Patients with Severe Combined Immunodeficiency

4481 Reduced Toxicity Conditioning for Non-Malignant Hematopoietic Cell Transplants

4624 Next Generation Sequence Minimal Residual Disease (NGS-MRD) Predicts Outstanding Event Free Survival (EFS) Regardless of Hematopoietic Cell Transplantation (HCT) Preparative Approach or Graft Alpha/Beta Depletion in Children with Acute Lymphoblastic Leukemia (ALL)

4706 Incidence and Cost of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with and without Multi-Organ Dysfunction: Analysis of the Premier Healthcare Database

Bita Fakri, MD, MPH

502 Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies

Huimin Geng, PhD

1239 Rationale for Targeting BCL6 in MLL-Rearranged B-ALL

2782 Ifitm3 Is Essential for PI(3,4,5)P3-Dependent B-Cell Activation and Leukemogenesis

746 Paraoxonase 2 Enables Initiation of B-ALL By Subverting Metabolic Gatekeeper Functions

748 Lgr5 Functions As a Critical Negative Regulator of Wnt/β-Catenin Signaling and Is Essential for B-Lymphopoiesis and Malignant B-Cell Transformation

3785 Targeting Unique Synthetic Lethal Interactions between PI3K and MYC in B-ALL

Dexter Hadley, MD, PhD

4395 Characterization of Monoclonal Gammopathy of Undetermined Significance Progression to Multiple Myeloma through Meta-Analysis of GEO Data

Michelle Hermiston, MD, PhD

805 Protein Translocation Inhibitors Overcome Cytokine-Induced Glucocorticoid Resistance in T-Cell Acute Lymphoblastic Leukemia

81 The Combination of Dexamethasone and Ruxolitinib Synergistically Attenuates Disease Manifestations in a Preclinical Model of Hemophagocytic Lymphohistiocytosis

Lawrence D. Kaplan, MD

1588 A Randomized Trial of EPOCH-Based Chemotherapy with Vorinostat for Highly Aggressive HIV-Associated Lymphomas: Updated Results Evaluating Impact of Diagnosis-to-Treatment Interval (DTI) and Pre-Protocol Systemic Therapy on Outcomes

2872 Response-Adapted Therapy with Infusional EPOCH Chemotherapy Plus Rituximab in HIV-Associated, B-Cell Non-Hodgkin's Lymphoma

4525 Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials

Andrew D. Leavitt, MD

1130 Von Willebrand Disease Minimize Menorrhagia (VWDMin) Trial

2060 Updated Follow-up of the Alta Study, a Phase 1/2, Open Label, Adaptive, Dose-Ranging Study to Assess the Safety and Tolerability of SB-525 Gene Therapy in Adult Patients with Severe Hemophilia A

Wendell Lim, PhD

SCI-24 Sensing and Sensibility: Programming Smarter Chimeric Antigen Receptor T Cells

Kathleen Dori Liu, MD, PhD

334 Changes in Intensive Care Unit Admission Rates, Organ Support, and Mortality in Patients with Acute Myeloid Leukemia: A Danish Nationwide Cohort Study

4783 Factors Associated with Risk and Prognosis of Intensive Care Unit Admission in Patients with Acute Myeloid Leukemia: A Danish Nationwide Cohort Study

Aaron C. Logan, MD, PhD

— Minimal Residual Disease in Hematologic Malignancies: Testing Considerations and Challenges

Mignon Loh, MD

286 Outcome in Adolescent and Young Adult (AYA) Patients Compared to Younger Patients Treated for High-Risk B-Lymphoblastic Leukemia (HR B-ALL): Report from the Children's Oncology Group Study AALL0232

1293 FLT3 Inhibitor Correlative Laboratory Assays Impact Outcomes in KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia (ALL) Patients Treated with Lestaurtinib: AALL0631, a Children's Oncology Group Study

2586 Open-Label, Multicenter, Phase 2/3 Study of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens (RC-P) in Patients with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to Escherichia coli–Derived Asparaginases

2649 Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Phase 1 Study

649 The Genomic Landscape of Childhood Acute Lymphoblastic Leukemia

650 Identification of New Risk Loci and Regulatory Mechanisms Influencing Genetic Susceptibility to Acute Lymphoblastic Leukaemia

652 Acute Lymphoblastic Leukemia with Zinc-Finger Protein 384 (ZNF384)-Related Rearrangements: A Retrospective Analysis from the Ponte Di Legno Childhood ALL Working Group

653 Germline RUNX1 Variation and Predisposition to T-Cell Acute Lymphoblastic Leukemia in Children

741 A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results from Children's Oncology Group Protocol AALL1621

824 Excellent Outcomes with Reduced Frequency of Vincristine and Dexamethasone Pulses in Children with National Cancer Institute (NCI) Standard-Risk B Acute Lymphoblastic Leukemia (SR B-ALL): A Report from Children's Oncology Group (COG) Study AALL0932

3947 RUNX2 Regulates Cell Migration in T-Cell Lineage Acute Lymphoblastic Leukemia

LBA-1 A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331

Steven R. Long, MD

2825 A Phase I/II Trial of Intratumoral CpG, Local Low-Dose Radiation, and Oral Ibrutinib in Patients with Low-Grade B-Cell Lymphoma

Tiffany Lucas, MD

— Using Technology in Medical Education

2409 Emicizumab-Kxwh for Previously Untreated Patients with Haemophilia: The Conversation Begins

Thomas G. Martin III, MD

— Approaches To Achieve the Best Possible Outcomes in Myeloma

3145 Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

602 Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial

Michael T. McManus, PhD

393 Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling

Rebecca L. Olin, MD, MSCE

175 Precision Medicine Treatment in Older AML: Results of Beat AML Master Trial

229 Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy

— Delivering Intensive Therapies to Older Adults with Hematologic Malignancies: Strategies to Personalize Care

3932 A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

4606 Cognitive Impairment Is Associated with Inferior Survival and Increased Non-Relapse Mortality in Older Allogeneic Hematopoietic Cell Transplant (alloHCT) Recipients: A Multicenter Retrospective Study

Rajalingam Raja, PhD

161 The Dendritic Cell HLA-Class-II/Therapeutic Factor VIII (FVIII) Peptidome Is Influenced in Unanticipated Ways By the B-Domain of FVIII and the FVIII Chaperon Protein, Von Willebrand Factor: The Outrigger and Glycosylation-Umbrella (GUMB) Hypotheses

2392 On the Role of F8 Sequence Mismatch and Class-II Human Leukocyte Antigen Binding in the Development of Neutralizing Antibodies (“Inhibitors”) Directed Against Therapeutic Factor VIII Proteins (tFVIIIs): Evidence from the PATH Study

Nareg Roubinian, MD

2452 The Presence and Persistence of Pregnancy-Associated Red Blood Cell Alloantibodies in Blood Donors

James L. Rubenstein, MD, PhD

1494 Potential Genetic and Immunologic Mechanisms of Therapeutic Resistance and Disease Progression in CNS Lymphoma Elucidated Via Whole Brain Autopsy Studies

Davide M. Ruggero, PhD

156 Regulation of eIF4E Guides a Unique Translational Program to Steer Erythroid Maturation

Peter H. Sayer, MD, PhD

733 Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart® Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients

Neil P. Shah, MD, PhD

1264 Cage Transcriptome Analysis Reveals BCL2A1 Upregulation in FLT3-ITD/D835 Dual Mutated AML Cells Harboring Complex Co-Mutations

705 Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia

4155 Association of High Body Mass Index with Response Outcomes in Patients with CML-CP Treated with Dasatinib Versus Imatinib in the First Line: Exploratory Post Hoc Analysis of the Phase 3 DASISION Trial

Nina D. Shah, MD

— CAR-T Therapy - Is it Prime-Time in Myeloma?

266 Primary Plasma Cell Leukemia Outcomes Remain Dismal Despite Novel Agents and Hematopoietic Cell Transplantation

1829 Daratumumab (DARA) Plus Lenalidomide Versus Lenalidomide Alone As Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma (NDMM) after Frontline Autologous Stem Cell Transplant (ASCT): Use of Minimal Residual Disease (MRD) As a Novel Primary Endpoint in the Phase 3 Auriga Study

3095 Cord Blood Regulatory T Cells Prevent Mutiple Myeloma Progression By Suppressing Inflammation

3184 Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME)

691 Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update

782 Breaking the Glass Ceiling of Age in Transplant in Multiple Myeloma

4459 A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in Combination with Daratumumab As a Salvage Regimen for Multiple Myeloma

927 Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy

Kristin A. Shimano, MD

2369 A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children

Catherine C. Smith, MD

14 Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial

1165 Direct Oral Anticoagulant Use and Outcomes in Patients with High and Intermediate Risk BCR-ABL-Negative Myeloproliferative Neoplasms

1440 Single Cell Sequencing Reveals Evolution of Tumor Heterogeneity of Acute Myeloid Leukemia on Quizartinib

— The Growing Landscape of FLT3 Inhibition in AML

Elliot Stieglitz, MD

1693 DNA Methylation As a Biomarker of Outcome in JMML: An International Effort Towards Clinical Implementation

Linda T. Vo, PhD

3710 Ezh1 Inhibits Commitment to Hemogenic Fate and HSPC Formation during Vertebrate Development

Arun P. Wiita, MD, PhD

1337 In Vitro-Selected Nanobody-Based Cellular Therapy Targeting CD72 for Treatment of Refractory B-Cell Malignancies

1803 Profiling the Cell Surface Landscape of Proteasome Inhibitor-Treated and –Resistant Multiple Myeloma to Guide Immunotherapy Targeting, Diagnosis, and Biology

3944 Signaling Input from Divergent Pathways Subverts Malignant B-Cell Transformation

333 Rates of Laboratory Adverse Events By Chemotherapy Course for Pediatric Acute Leukemia Patients within the Leukemia Electronic Abstraction of Records Network (LEARN)

Lena E. Winestone, MD, MSHP

3415 Disparities in Barriers and Facilitators of Acute Leukemia Diagnosis in Young Patients

703 Area-Based Socioeconomic Disparities in Survival of Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the Children's Oncology Group

4753 Health Care Costs Associated with Contemporary Chronic Myelogenous Leukemia (CML) Therapy Compared to Other Hematologic Malignancies (HEM)

John S. Witte, PhD

4379 Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans

Sandy W. Wong, MD

143 First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial

1907 Dynamics of Activated CD8+ T-cells and Decreased Osteoclasts in the Tumor Microenvironment are Associated with Clinical Efficacy of Anti-PD-L1 and Anti-CD38 Combination Treatment in Relapsed or Refractory Multiple Myeloma

Joanna C. Yang, MD, MPH

2834 A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

4137 Highly Favorable Outcomes with Salvage Radiation Therapy Followed By Autologous Transplant in Relapsed and Refractory DLBCL Patients with Minimal or No Response to Salvage Chemotherapy

Elad Ziv, MD

4366 Association between a Polygenic Risk Score for Multiple Myeloma Risk and Overall Survival

4397 Germline Variation Predicts Treatment Response in Multiple Myeloma


UCSF
University of California
San Francisco